

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(12)

Oversættelse af europæisk patentskrift

(10) **DK/EP 4288547 T3**

-
- (51) Int.Cl.: **C 12 N 15/115 (2010.01)** **A 61 K 31/713 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2025-01-13**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2024-10-09**
- (86) Europæisk ansøgning nr.: **22716269.0**
- (86) Europæisk indleveringsdag: **2022-04-08**
- (87) Den europæiske ansøgnings publiceringsdag: **2023-12-13**
- (86) International ansøgning nr.: **EP2022059466**
- (87) Internationalt publikationsnr.: **WO2022214670**
- (30) Prioritet: **2021-04-09 WO PCT/EP2021/059328**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Berlin Cures GmbH, Knesebeckstrasse 59-61, 10719 Berlin, Tyskland**
- (72) Opfinder: **HABERLAND, Annkathrin, , 13086 Berlin, Tyskland**
MÜLLER, Johannes, , 10717 Berlin, Tyskland
WALLUKAT, Gerd, , 13129 Berlin, Tyskland
GÖTTEL, Peter, , 14612 Falkensee, Tyskland
- (74) Fuldmægtig i Danmark: **Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S, Danmark**
- (54) Benævnelse: **APTAMERER TIL BRUG I BEHANDLINGEN AF CORONAVIRIDAE-INFEKTIONER**
- (56) Fremdragne publikationer:
YANLING SONG ET AL: "Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein", 4 April 2020 (2020-04-04), XP055745454, Retrieved from the Internet <URL:https://s3-eu-west-1.amazonaws.com/itempdf74155353254prod/12053535/Discovery_of_Aptamers_Targeting_Receptor-Binding_Domain_of_the_SARS-CoV-2_Spike_Glycoprotein_v2.pdf> [retrieved on 20201030], DOI: 10.26434/chemrxiv.12053535.v2
KA TO SHUM ET AL: "Differential Inhibitory Activities and Stabilisation of DNA Aptamers against the SARS Coronavirus Helicase", CHEMBIOCHEM, vol. 9, no. 18, 15 December 2008 (2008-12-15), pages 3037 - 3045, XP055730769, ISSN: 1439-4227, DOI: 10.1002/cbic.200800491
JANG KYOUNG JIN ET AL: "Isolation of inhibitory RNA aptamers against severe acute respiratory syndrome (SARS) coronavirus NTPase/Helicase", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 366, no. 3, 17 December 2007 (2007-12-17), pages 738 - 744, XP029239517, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2007.12.020
CAROLINA ROXO ET AL: "G-Quadruplex-Forming Aptamers-Characteristics, Applications, and Perspectives", MOLECULES, vol. 24, no. 20, 21 October 2019 (2019-10-21), pages 3781, XP055656334, DOI: 10.3390/molecules24203781
W. O. TUCKER ET AL: "G-quadruplex DNA Aptamers and their Ligands: Structure, Function and Application",

Fortsættes ...

CURRENT PHARMACEUTICAL DESIGN, vol. 18, no. 14, 1 March 2012 (2012-03-01), NL, pages 2014 - 2026, XP055533421, ISSN: 1381-6128, DOI: 10.2174/138161212799958477

JINZHI TAN ET AL: "The SARS-Unique Domain (SUD) of SARS Coronavirus Contains Two Macrodomains That Bind G-Quadruplexes", PLOS PATHOGENS, vol. 5, no. 5, 15 May 2009 (2009-05-15), pages e1000428, XP055730797, DOI: 10.1371/journal.ppat.1000428

SEONG-JE CHO ET AL: "Novel system for detecting SARS coronavirus nucleocapsid protein using an ssDNA aptamer", JOURNAL OF BIOSCIENCE AND BIOENGINEERING, ELSEVIER, AMSTERDAM, NL, vol. 112, no. 6, 11 August 2011 (2011-08-11), pages 535 - 540, XP028339518, ISSN: 1389-1723, [retrieved on 20110824], DOI: 10.1016/J.JBIOSC.2011.08.014

DESCRIPTION

Description

Technical field

[0001] The present invention relates to new aptamer molecules for use in therapy of infections caused by viruses from the *Coronaviridae* family, a method of preventing infection caused by viruses from the *Coronaviridae* family *in vitro/ex vivo*, a pharmaceutical composition and a kit comprising such aptamer molecules, and the use of aptamer molecules for preventing infection of somatic cells with a virus from the *Coronaviridae* family. The present invention also relates to affinity molecules binding to specific and newly identified epitopes within a key enzyme of *Coronaviridae* viruses.

Background of the Invention

[0002] The emergence of a novel and highly pathogenic coronavirus (SARS-CoV-2) and its rapid international spread poses a serious global public health emergency. Similar to those infected by other pathogenic Coronavirus strains such as severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, patients infected by SARS-CoV-2 manifest a range of symptoms including dry cough, fever, headache, dyspnea and pneumonia with an estimated mortality rate in the range of 3-5%.

[0003] Since the initial outbreak in December of 2019, SARS-CoV-2 has spread to 212 countries, areas and territories worldwide overall. As of April 8, 2020, 1,317,130 infections with the virus have been confirmed globally with 74,304 confirmed deaths of infected patients (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>).

[0004] Currently, various cities and countries across the world are under lockdown to various extents to minimize continued spread, and the WHO has announced a Public Health Emergency of International Concern (PHEIC) due to the rapid and global dissemination of SARS-CoV-2.

[0005] Phylogenetic analysis on the coronavirus genomes has revealed that SARS-CoV-2 is a new member of the *Betacoronavirus* genus, which includes SARS-CoV, MERS-CoV, bat SARS-related coronaviruses (SARSr-CoV), as well as others identified in humans and diverse animal species.

[0006] Each coronavirus contains four structural proteins, including spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. Among them, the Spike glycoprotein or S protein plays the most important role in viral attachment, fusion and entry, and it serves as the most promising target for development of antibodies, entry inhibitors and vaccines. The S protein mediates viral entry into host cells by first binding to a host receptor through the receptor-binding domain (RBD) in the S1 subunit and then fusing the viral and host membranes through the S2 subunit (Lu, G.

et al. Nature 500, 227-231 (2013).). Thus, the homotrimeric spike glycoprotein (S1 subunit and S2 subunit in each spike monomer) on the virus envelope is used to bind their cellular receptors. Such binding triggers a cascade of events leading to the fusion between cell and viral membranes for cell entry.

[0007] SARS-CoV and MERS-CoV RBDs recognize different receptors. SARS-CoV recognizes angiotensin-converting enzyme 2 (ACE2) as its receptor, whereas MERS-CoV recognizes dipeptidyl peptidase 4 (DPP4) as its receptor. Similar to SARS-CoV, SARS-CoV-2 also recognizes ACE2 as its host receptor binding to viral S protein (Zhou, P., et al. Nature 579, 270-273 (2020).).

[0008] Previous cryo-EM studies of the SARS-CoV Spike and its interaction with the cell receptor ACE2 have shown that binding to ACE2 receptor on the target somatic cell is a critical initial step for the SARS-CoV to enter into target cells. Recent studies also pointed to the important role of ACE2 in mediating entry of SARS-CoV-2 (Walls, A. C. et al. Cell S0092-8674(20)30262-2 (2020). <https://doi.org/10.1016/j.cell.2020.02.058>. and Hoffmann, M. et al. Cell S0092-8674 (20)30229-4 (2020). <https://doi.org/10.1016/j.cell.2020.02.052>).

[0009] HeLa cells expressing ACE2 are susceptible to SARS-CoV-2 infection while those lacking the receptor are not. *In vitro* binding measurements also showed that the SARS-CoV-2 receptor-binding domain (RBD) binds to ACE2 with an affinity in the low nM range, indicating that the RBD is the key functional component within the S1 subunit of the Spike glycoprotein responsible for binding of SARS-CoV-2 by ACE2.

[0010] More recently, it could be demonstrated that SARS-CoV2 also uses heparan sulfate as co-factor or cell-attachment factor enabling the subsequent successful ACE-2 mediated cell entry. A preceding contact of the RBD with heparan sulfate may function as a "virus-collector", necessary for subsequent cell-uptake. Here, the positively charged aminoacids of the RBD of SARS-CoV-2 are discussed as potential binding partners to heparan sulfate and heparin (Clausen et al., 2020, Cell 183, 1043-1057.e15.).

[0011] In summary, the Spike protein of each respective Coronavirus is crucial and relevant for the infectiousness and pathogenicity of the virus. At this stage, there is significant activity in research and development to identify novel and additional agents which are directed against Coronavirus spike proteins and thus able to interfere with the infection process. While antibodies may be developed which target this moiety selectively, it may be even more advantageous to identify (small) molecules which have passed Phase I clinical trials and thus can be safely administered to patients.

[0012] In addition, a virus and the viral infection cycle has more vulnerable sites which can theoretically be attacked by a substance. In the case of oligonucleotide-based drugs, also known as aptamers, several such critical sites which are vulnerable to interference by such molecules had been identified and described before. Additional potential target sites for drugs including small molecules, antibody-derived biologics as well as aptamers are enzymes involved in the replication process of RNA viruses. The characterization of such novel target sites and affinity molecules directed against such novel target sites would supplement the tool kit for combatting *Coronaviridae* infections.

[0013] An overview of antivirally active aptamers has been provided by González et al. and Zou et al. (González, V.M. et al., 2016. Use of Aptamers as Diagnostics Tools and Antiviral Agents for Human

Viruses. Pharmaceuticals (Basel) 9. <https://doi.org/10.3390/ph9040078> and Zou et al., 2019. Application of Aptamers in Virus Detection and Antiviral Therapy. Front Microbiol 10, 1462. <https://doi.org/10.3389/fmicb.2019.01462>.

[0014] In fact, anti-Coronaviral therapy has further been reported, based on the isolation of inhibitory RNA and DNA aptamers, respectively, against severe acute respiratory syndrome (SARS) coronavirus NTPase/Helicase. Among such antivirally active aptamers, the anti-influenza aptamer A22 (-AATTAACCCTCACTAAAGGGCTGAGTCTCAAACCGCAATACACTGGTTGTATGGTCGAATAAGTTAA; SEQ ID No. 6) blocking the receptor binding region of hemagglutinin should be mentioned. Besides the virus's cell entry mediator as a target according to the present invention, other virus-target binding sites have also already been identified such as the nucleoprotein of the influenza virus (Negri et al., 2012. Direct Optical Detection of Viral Nucleoprotein Binding to an Anti-Influenza Aptamer. Anal Chem. 2012 Jul 3; 84(13): 5501-5508.).

[0015] Recent publications based on newly raised data from COVID-19 patients suggest or even prove that SARS-CoV-2 can reach the blood stream and various areas of the body, where it appears to cause microthromboses. Such microthrombosis is currently seen as one of the main causes of death of COVID-19 patients (Ackermann M. et al., N Engl J Med. 2020 doi: 10.1056/NEJMoa2015432; Varga Z et al., The Lancet 2020 doi: 10.1016/S0140-6736(20)30937-5; Wichmann D et al. Annals of Internal Medicine 2020 doi: 10.7326/M20-2003).

[0016] Over the course of the pandemic, it has become apparent e.g. in an Italian study that a high percentage of patients of more than 85% exhibit persistent symptoms even after recovering from COVID-19 (Carfi A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group (2020) Persistent Symptoms in Patients After Acute COVID-19. JAMA 324:603-605. <https://doi.org/10.1001/jama.2020.12603>). Similar results concerning the extent of post-COVID-19 symptoms have been confirmed in a German study that showed more than 75% of their investigated COVID-19 patients exhibiting post-disease symptoms (Puntmann VO, Carerj ML, Wieters I, et al (2020) Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. <https://doi.org/10.1001/jamacardio.2020.3557>).

[0017] The complex of persisting symptoms observed after the active SARS-CoV-2 infection and the disease COVID-19 has subsided is commonly termed Post-COVID syndrome, Long COVID, PASC (Post-Acute Sequelae of SARS-CoV-2 infection), CCS (chronic COVID syndrome) or long-haul COVID.

[0018] These symptoms may include one or more neurological disturbances, such as chronic fatigue syndrome, postural orthostatic tachycardia syndrome (PoTS), dysautonomia, transverse myelitis, acute necrotising myelitis, Guillain-Barré syndrome and others, as well as cardiovascular implications, such as myocardial inflammation, arrhythmia, tachycardia, bradycardia, and atrioventricular (AV) block, which may even escalate to cardiac arrest.

[0019] Accordingly, new therapeutic agents are required not only for prevention and treatment of active SARS-CoV-2 infections but also for prevention and treatment of symptoms following such infections in the form of Long COVID. Interestingly, a connection was recently implicated between

Long COVID and autoimmunity. In this regard, a SARS-CoV-2 triggered autoimmune response was suggested as possible key factor for severity and longevity (Long-COVID) of the disease (Khamsi R 2021, Nature 590(7844):29-31.).

[0020] Any new compounds and compositions may theoretically find use in many clinically relevant applications within a short time frame, including mitigating and curing symptoms caused by *Coronaviridae* in patients.

[0021] Accordingly, it is an object of the present invention to provide new molecules for the use in therapy of a subject suffering from or having overcome an infection with a virus from the family *Coronaviridae*.

[0022] Furthermore, it is another object of the present invention to provide a method for preventing infection of somatic cells with a virus from the *Coronaviridae* family.

[0023] It is also an object of the present invention to provide a pharmaceutical composition and a kit which may be used against such viral infections.

[0024] It is a further object of the present invention to provide a use of novel molecules for preventing infection of somatic cells with a virus from the *Coronaviridae* family.

[0025] In view of the recently recognized relevance of microthrombosis in the course of COVID-19 disease, it is also an object to provide new molecules which are effective against infection with a virus from the family *Coronaviridae* and at the same time show anticoagulatory effects.

[0026] It is further an object of the present invention to provide affinity molecules which are directed against novel target sites within the *Coronaviridae* replication machinery.

Summary of the Invention

[0027] The aforementioned objects are solved by the aspects of the present invention as specified hereinafter.

[0028] According to the first aspect of the present invention, an aptamer is provided for use in therapy of a subject by treating, curing or preventing further progression of infection with a virus from the *Coronaviridae* family, wherein the aptamer comprises a nucleic acid sequence of SEQ ID No. 1 (GGT TGG TGT GGT TGG) and/or a nucleic acid sequence being at least 80% identical to SEQ ID No. 1.

[0029] In a preferred embodiment of the first aspect of the invention, the subject is a mammal, preferably the subject is a human.

[0030] In one preferred embodiment of the first aspect of the invention, the infection is caused by a virus from the genus *Betacoronavirus*, preferably from the subgenus *Sarbecovirus* or *Merbecovirus*, more preferably by a virus selected from the group comprising MERS-CoV, SARS-CoV and SARS-CoV-2.

[0031] In another preferred embodiment of the first aspect of the invention, the infection is caused by a virus from the subgenus *Sarbecovirus*, preferably from the species *Severe acute respiratory syndrome-related coronavirus*, even more preferably one of SARS-CoV and SARS-CoV-2

[0032] In a specifically preferred embodiment of the first aspect of the invention, the infection is caused by SARS-CoV-2.

[0033] In one preferred embodiment of the first aspect of the invention, the aptamer has anticoagulant activity, preferably the aptamer is able to prolong coagulation time measured as partial thromboplastin time (PTT or alternatively aPTT) of human calibration plasma to 60 seconds or more at an aptamer concentration of 0.03 mg/ml and/or the aptamer is able to lower the prothrombin time (Quick value) of human calibration plasma to 40% or less at an aptamer concentration of 0.03 mg/ml.

[0034] In another preferred embodiment of the first aspect of the invention, the aptamer selectively interacts with or binds to human thrombin, preferably the K_D value for binding of the aptamer to human thrombin is 1 μ M or less.

[0035] In a preferred embodiment of the first aspect of the present invention, the aptamer interferes with the infection of somatic cells by selectively interacting with the Spike (S) glycoprotein, preferably with the Receptor-binding domain (RBD) of the Spike (S) glycoprotein, of the virus, more preferably by preventing or interfering with the interaction of the Spike glycoprotein of the virus and the angiotensin-converting enzyme 2 (ACE2) or the dipeptidyl peptidase 4 (DPP4), even more preferably the ACE2, of a subject host cell.

[0036] In a more preferred embodiment of the previous embodiment of the first aspect of the present invention, the Receptor-binding domain of the Spike glycoprotein has a sequence of SEQ ID NO: 2 (SARS-CoV-2 Spike RBD) or SEQ ID NO: 3 (SARS-CoV Spike RBD) or SEQ ID NO: 4 (MERS-CoV Spike RBD), preferably wherein the Receptor-binding domain of the Spike glycoprotein has a sequence of SEQ ID NO: 2 or SEQ ID NO: 3, preferably wherein the Spike glycoprotein has a sequence of SEQ ID NO: 2.

[0037] In one preferred embodiment of the present invention, the aptamer is administered to the subject by systemic delivery or pulmonary delivery, preferably by pulmonary delivery, more preferably by inhalation.

[0038] According to the second aspect of the present invention, an aptamer is provided for use in therapy of a subject by treating, curing or preventing disease symptoms associated with Long COVID in a patient having overcome an infection with a virus from the *Coronaviridae* family, wherein the aptamer comprises a nucleic acid sequence of SEQ ID No. 1 (GGT TGG TGT GGT TGG) and/or a nucleic acid sequence being at least 80% identical to SEQ ID No. 1.

[0039] In a preferred embodiment of the second aspect, the disease symptoms comprise one or more from the group comprising neurological symptoms, such as chronic fatigue syndrome, postural orthostatic tachycardia syndrome (PoTS), dysautonomia, tremor, attention deficit, anomia aphasia, neuropathy, transverse myelitis, acute necrotising myelitis, and Guillain-Barré syndrome, cardiovascular symptoms, such as myocardial inflammation, arrhythmia, tachycardia, bradycardia,

hypertension, and atrioventricular (AV) block, dermatological symptoms, such as alopecia and eczema, or gastrointestinal diseases.

[0040] In another preferred embodiment of the second aspect of the present invention, the aptamer is used to inhibit the interaction of autoantibodies specific for a G-protein coupled receptor with its target proteins.

[0041] In yet another preferred embodiment of the second aspect of the present invention, the aptamer is for use in the treatment of a patient in which autoantibodies against G-protein coupled receptors can be detected.

[0042] In one preferred embodiment of the second aspect of the present invention, the patient exhibits functional autoantibodies against G-protein coupled receptors, preferably functional autoantibodies specific for any one of the human G-protein coupled receptor adrenergic alpha-1 receptor, adrenergic beta-2 receptor, endothelin 1 ETA receptor, muscarinic M₂ receptor, angiotensin II AT1 receptor, MAS-receptor and/or the nociception receptor, more preferably for any one of the adrenergic beta-2 receptor, muscarinic M₂ receptor, angiotensin II AT1 receptor, MAS-receptor, particularly preferably wherein the patient exhibits an antibody pattern comprising functional autoantibodies specific for each of the adrenergic beta-2 receptor, muscarinic M₂ receptor, angiotensin II AT1 receptor, and MAS-receptor.

[0043] According to the third aspect of the present invention, a method of preventing infection of somatic cells with a virus from the *Coronaviridae* family by using an aptamer is provided, wherein the method is carried out *in vitro/ex vivo* and wherein the aptamer comprises a nucleic acid sequence of SEQ ID No. 1 (GGT TGG TGT GGT TGG) and/or a nucleic acid sequence being at least 80% identical to SEQ ID No. 1.

[0044] In a preferred embodiment of the third aspect of the present invention, the cell is a mammalian cell, preferably wherein the cell is a human cell.

[0045] According to the fourth aspect of the present invention, a pharmaceutical composition is provided comprising an aptamer for use according to the first aspect of the present invention and at least one pharmaceutically acceptable excipient.

[0046] In a preferred embodiment of the fourth aspect of the present invention, the pharmaceutical composition for use according to the first aspect is for administration to the subject by systemic delivery or pulmonary delivery, preferably by pulmonary delivery, more preferably by inhalation.

[0047] According to the fifth aspect of the present invention, a kit is provided comprising at least one aptamer for use according to the first aspect of the present invention and a container.

[0048] According to the sixth aspect of the present invention, the use of the aptamer as defined in the first aspect of the present invention is provided for preventing infection of somatic cells with a virus from the *Coronaviridae* family, wherein the aptamer is used *in vitro/ex vivo*.

[0049] According to the seventh aspect of the present invention, affinity molecules are provided that specifically bind to a peptide of amino acid sequence Leu-Tyr-Arg-Asn-Arg-Asp-Val (LYRNRDV; SEQ

ID NO: 9) and/or His-Arg-Phe-Tyr-Arg-Leu-Ala-Asn (HRFYRLAN; SEQ ID NO: 10) of the RNA-dependent RNA polymerase of the Severe acute respiratory syndrome coronavirus 2.

[0050] In a preferred embodiment of the seventh aspect of the present invention, the affinity molecule is a small molecule having a molecular weight of at most 900 Daltons, more preferably the affinity molecule is a small molecule from any one small molecule collection from the group comprising the University of Cincinnati Compound Collection, the DiscoveryProbe™ Bioactive Compound Library Plus from ApexBio Technology LLC, and the SARS-CoV-2 Screening Library from Cayman Chemical.

[0051] In another preferred embodiment of the seventh aspect of the present invention, the affinity molecule is a peptide-based compound, more preferably an antibody or a binding fragment thereof.

[0052] In one preferred embodiment of the seventh aspect of the present invention, the affinity molecule is an aptamer or oligonucleotide.

[0053] In an eighth aspect of the present invention, the affinity molecule of the seventh aspect is provided for use as a medicament.

[0054] In a ninth aspect of the present invention, the affinity molecule of the seventh aspect is provided for use in therapy of a subject by treating, curing or preventing further progression of infection with a virus from the *Coronaviridae* family.

Description of Figures

[0055]

Figure 1 shows NMR-analysis of quadruplex formation of BC 007 in presence of peptide No. 4 (a 6 aa peptide-sequence of SEQ ID NO: 5; **YRLFRK**) from the spike protein of SARS-CoV-2; upper spectrum: 1H-NMR spectrum of a 1: 1 mixture of BC007 and peptide No. 4 with the sequence YRLFRK; middle spectrum: the spectrum of peptide No. 4 of SEQ ID NO: 5 in pure water; bottom spectrum: spectrum of the quadruplex structure of BC007 in the presence of KCl.

Figure 2 shows the same spectra of Figure 1, wherein the view is zoomed into the range between 8.5-6.0 ppm; middle und bottom: pure substances show rather sharp signals, which are broadened and shifted in their position in the upper spectrum due to the interaction of the two substances with each other.

Figure 3 shows inhibition of SARS-CoV-2 replication by BC 007 in cell culture based on antiviral dose-response effects of BC 007 in VeroFM and Calu-3 cells.

Figure 4 shows an ELISA test of the binding of the aptamer of the present invention BC007 (SEQ ID NO: 1) to immobilized human thrombin.

Figure 5 shows the results of a determination of coagulation inhibition caused by the aptamers BC007 (SEQ ID NO: 1) and AS1411 (SEQ ID NO: 7), respectively, measured as (A) partial thromboplastin time (PTT) and as (B) prothrombin time (Quick) value.

Figure 6 shows NMR analysis of quadruplex formation of BC007 in the presence of peptide LYRNRDV (top; SEQ ID NO: 9) and peptide HRFYRLAN (bottom; SEQ ID NO: 10) of the RNA-dependent RNA polymerase of SARS-CoV-2 (full-length sequence as SEQ ID NO: 8), wherein both peptides were able to induce the quadruplex fold which is indicative for successful and specific binding.

Figure 7 shows an ITC (isothermal titration calorimetry) analysis of BC007 titrated with peptide HRFYRLAN (SEQ ID NO: 10) of the RNA-dependent RNA polymerase of SARS-CoV-2; top - thermogram; bottom - binding isotherm.

Figure 8 shows ITC analysis of BC007 titrated with a comparative, highly charged peptide control sequence, NRKRISN (SEQ ID NO: 11), which is also present in the Spike RBD of SARS-CoV-2; top - thermogram; bottom - binding isotherm.

Figure 9 shows a comparison of NMR analyses of BC007 in the presence of control peptide NRKRISN (SEQ ID NO: 11), and peptide No. 4 (SEQ ID NO: 5; **YRLFRK**) from the spike protein of SARS-CoV-2.

Figure 10 shows an overview of Long COVID symptoms and accompanying GPCR autoantibodies in patient sera.

Figure 11 shows the measurement of functionally active autoantibodies which target G-protein coupled receptors from serum of patients suffering from Post-COVID-symptoms in a bioassay. **A:** positive chronotropic autoantibodies against the beta2-adrenoceptor (beta2-R), the nociceptin receptor (nociceptin-R), the angiotensin II AT1 receptor (AT1), and the alpha1-adrenoceptor (alpha1-R); these measurements were done in the presence of the antagonist Atropine, A779, and BQ123 which block the antibodies that exert a negative chronotropic effect; when pre-incubated with the aptamer BC 007, the functional activity was abolished. Controls were samples of healthy donors. **B:** negative chronotropic autoantibodies against the MAS-receptor (MAS-R), the muscarinic M2-receptor (M2-R), the endothelin receptor (ETA-R); here, the activity of positive chronotropic acting autoantibodies was blocked by ICI118.551, J113397, losartan, and urapidil; when pre-incubated with the aptamer BC 007, the functional activity was abolished. Controls were samples of healthy donors; Neuro* = neurological symptoms; Cardiovasc** = cardiovascular symptoms, n.a. = not applicable, PoTS = postural orthostatic tachycardia syndrome; NOC- γ AAB[§] = functionally active autoantibody against the nociceptin receptor, β 2- γ AAB[§] = autoantibody targeting the beta1-adrenoceptor, α 1- γ AAB[&] = autoantibody targeting the alpha1-adrenoceptor, ETA- γ AAB⁺ = autoantibody targeting the endothelin receptor, M2- γ AAB[%] = autoantibody targeting the muscarinic receptor, AT1- γ AAB[?] = autoantibody targeting the angiotensin II AT1 receptor, MAS- γ AAB[#] = autoantibody targeting the MAS receptor

Detailed Description of the Invention

[0056] The present invention is based on the identification of novel compounds which are able to

selectively interact with the Spike protein of viruses of the *Coronaviridae* family and thus are expected to interfere with the infection of somatic cells by such viruses. Furthermore, the inventors successfully recognized that specific aptamer molecules are able to inhibit the infectious activity and replication of such viruses in human cells.

[0057] The present inventors intensively studied the interaction of the aptamer of SEQ ID NO: 1, which is also commonly referred to as thrombin-binding aptamer or BC007, with several binding partners, such as thrombin. While investigating the specificities of the interaction between BC007 and thrombin using NMR technology, it could be detected that not the entire, full-length thrombin-molecule was required for strong binding to BC007 as evidenced by adoption of an NMR-detectable quadruplex structure by BC007.

[0058] In fact, much shorter peptide sequences taken from the binding moiety were recognized to lead to the same results (data not shown). In fact, it became clear that peptides taken from full-length thrombin that cause quadruplex folds of BC007 consist of or possess sequence motifs containing several amino acids with side chains having positive charges, preferably of arginine. These peptides could represent solvent-facing surfaces due to their positive charge which may then selectively be bound by the claimed aptamers in thrombin as well as in other proteins such as Spike proteins of viruses from the *Coronaviridae* family.

[0059] Faced with the problems caused by the current outbreak of SARS-CoV-2 and other Coronavirus-related infections, the present inventors considered if the claimed aptamer molecules could potentially have a function as agents against Coronavirus infections.

[0060] Surprisingly, the inventors learned that Spike proteins of different Coronavirus strains, in particular sequences belonging to the receptor-binding domains thereof, possess sequence motifs containing several amino acids with side chains having positive charges, such as Arginine-rich-clusters (cf. Hoffmann et al., 2020, supra).

[0061] Based on this information together with substantial experience from studying the interaction of specific aptamers with thrombin, the inventors successfully identified representative clusters of positively charged amino acids and Arginine-rich sequence sections (e.g. clusters) within the receptor-binding domain of the virus Spike protein of SARS-CoV-2 as well as previously unknown target peptides within the RNA-dependent RNA polymerase of *Coronaviridae* viruses.

[0062] Peptide No. 4 (with the amino acid sequence YRLFRK; SEQ ID NO: 5) which is part of the receptor-binding domain of the S1 subunit of the Spike protein of SARS-CoV-2 was selected as a representative peptide for binding studies with BC007. It has surprisingly been observed that there is in fact strong interaction between Peptide No. 4 and BC007 which leads to BC007 adapting a quadruplex fold (see Figure 1 and 2 and Example 1 in the Examples section below).

[0063] Such strong interaction is highly plausible and likely to persist in the full-length molecule, the whole Spike protein as well as entire virus particles, in which the Spike protein is responsible for infectivity and pathogenicity of viruses of the *Coronaviridae* family. Also, based on the presence of clusters of positively charged amino acids within the Spike protein of other virus strains from the *Coronaviridae* family, it is plausible that the present invention is useful against other such viruses as well.

[0064] Departing from this evidence for strong interaction of the aptamer of the present invention with a Spike sequence motif of SARS-CoV-2, the inventor proceeded to carry out an analysis of the inhibitory activity of the inventive aptamer on SARS-CoV-2 infecting human cells.

[0065] Surprisingly, the aptamer of the present invention not only demonstrated a very efficient inhibition of the viral activity of SARS-CoV-2 but actually appeared to surpass other antiviral agents currently discussed as potential therapeutic options for COVID-19 (see Example 2).

[0066] These results evidently reflect the therapeutic effect on which the therapeutic application of using the inventive aptamer in treating, curing or preventing an infection with viruses of the *Coronaviridae* family is based.

[0067] In addition to the observed effects, it has previously been reported that G-quadruple oligonucleotide-structures cause the development of anti-viral effects in e.g. HIV infection, not only by inhibiting HIV entry into host cells (ISIS5320) but also inhibiting HIV integrase itself (T30177 or AR177, the first integrase inhibitor in clinical trials) (for review see Roxo, C., et al., 2019. G-Quadruplex-Forming Aptamers-Characteristics, Applications, and Perspectives. *Molecules* 24. <https://doi.org/10.3390/molecules24203781>

[0068] HIV is, just like SARS-CoV-2 and other *Coronaviridae* viruses, an ssRNA virus, which means that virus replication steps are comparable. It is, therefore, highly probable that the claimed aptamers which may adopt a G-quadruplex-like fold upon interaction with binding partners might also be able to inhibit the SARS-CoV-2 integrase or other vulnerable sites in addition to a direct interaction with the Spike protein.

[0069] Furthermore, recent data indicating a significant relevance of microthrombosis in deaths of patients suffering from COVID-19, molecules having antithrombotic and anticoagulatory effects are studied in the context of *Coronaviridae* infections. The ability of the presently claimed aptamer molecules to combat the infection with a virus from the family *Coronaviridae* and at the same time show anticoagulatory effects makes the present invention even more suitable for use against COVID-19 and other *Coronaviridae*-associated diseases.

[0070] This is a particular advantage of the aptamer of the present invention over other aptamers recently suggested as therapeutic agents against COVID-19, such as the aptamer AS1411 (SEQ ID NO: 7). Such comparative aptamers are devoid of any antithrombotic or anticoagulatory effects and thus lack the dual mode of attack of the present invention. AS1411 was originally developed as a synthetic DNA molecule that binds a protein called nucleolin found on the surface of cells. Based on this activity, it has been previously studied as an experimental drug for cancer treatment.

[0071] According to one aspect of the present invention, an aptamer is provided for use in therapy of a subject by treating, curing or preventing further progression of infection with a virus from the *Coronaviridae* family, wherein the aptamer comprises a nucleic acid sequence of SEQ ID No. 1 (GGT TGG TGT GGT TGG) and/or a nucleic acid sequence being at least 80% identical to SEQ ID No. 1.

[0072] Within the present invention, a use in treating of an infection with a virus shall also mean that the first infection of a subject may be prevented by the aptamer for use according to the invention. In

addition and more importantly, the aptamer for use according to the present invention shall be used in treating, curing or preventing further progression of infection in subjects that have been identified as being infected with a virus from the *Coronaviridae* family.

[0073] With regard to the new findings of Clausen et al., 2020 as discussed above, it is further likely and plausible that the aptamer of SEQ ID No. 1 might also compete with a heparin binding motive of RBD. Said aptamer has already been reported to selectively interact with the heparin binding motive of thrombin (exosite 2; cf. Padmanabhan and Tulinsky, 1996 Acta Crystallogr D Biol Crystallogr 52:272-282) besides its well known and investigated binding onto exosite 1, the fibrinogen binding site of thrombin. Due to an increased presence of negatively charged amino acids at such heparin binding sites, binding of SEQ ID No. 1 at the heparin binding sites of the RBD of SARS-CoV-2 in analogy to the known binding to the heparin binding motive of thrombin appears plausible.

[0074] According to one embodiment of the present invention, the aptamer further interferes with the infection of somatic cells by selectively interacting with the cellular heparan sulfate of a subject host cell.

[0075] According to a preferred embodiment of the present invention, the subject in which the viral infection should be treated, cured or further progression thereof prevented is a vertebrate, more preferably the subject is a mammal. Within the meaning of the present invention, the group of mammals includes but is not limited to rats, mice, ferrets, rabbits, cats, dogs, horses, cattle, cows, pigs, sheep, non-human primates and humans. Most preferably, the subject is a human.

[0076] In a preferred embodiment of the present invention, the aptamer of the present invention disclosed and described herein comprises a nucleic acid sequence of SEQ ID No. 1 (GGT TGG TGT GGT TGG) and/or a nucleic acid sequence being at least 80% identical to SEQ ID No. 1. In another more preferred embodiment, the aptamer comprises the nucleic acid sequence of SEQ ID No. 1 (GGT TGG TGT GGT TGG), in particular the aptamer consists of the nucleic acid sequence of SEQ ID No. 1 (GGT TGG TGT GGT TGG).

[0077] The determination of percent identity between two sequences is accomplished according to the present invention by using the mathematical algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci. USA (1993) 90: 5873-5877). Such an algorithm is the basis of the BLASTN and BLASTP programs of Altschul et al. (J. Mol. Biol. (1990) 215: 403-410). BLAST nucleotide searches are performed with the BLASTN program. To obtain gapped alignments for comparative purposes, Gapped BLAST is utilized as described by Altschul et al. (Nucleic Acids Res. (1997) 25: 3389-3402). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs are used.

[0078] According to a more preferred embodiment of the present invention, aptamer sequences form part of the invention which consist of or comprise a nucleic acid sequence being at least 85% identical to the individualized aptamer sequences which are disclosed herein, even more preferably at least 90% identical, particularly preferably at least 95% identical.

[0079] For the purpose of this invention, the term "aptamer" refers to an oligonucleotide that binds specifically and with high affinity to a target molecule. Under defined conditions, aptamers may fold into a specific three dimensional structure. In one preferred embodiment of the present invention, the

claimed aptamers interact specifically and with high affinity with the target sequence.

[0080] According to a preferred embodiment, the aptamers interact with a sequence within the Spike glycoprotein of a virus from the *Coronaviridae* family, preferably to a sequence within the S1 subunit, more preferably to a sequence within the receptor binding domain thereof. According to one embodiment of the present invention, the aptamer binds to a region within the virus sequence which has two or more positively charged amino acids, more preferably arginine, within a stretch of seven amino acids.

[0081] The aptamer of the invention comprises or consists of a sequence of nucleic acid molecules, the nucleotides. According to a preferred embodiment, the aptamer of the invention consists of a nucleotide sequence as defined herein.

[0082] The aptamer of the invention preferably comprises unmodified and/or modified D- and/or L-nucleotides. According to the common one letter code of nucleic acid bases "C" or stands for cytosine, "A" or stands for adenine, "G" or stands for guanine, and "T" or stands for thymine if the nucleotide sequence is a DNA sequence and "T" or stands for a uracil nucleotide if the nucleotide sequence is a RNA sequence. If not indicated below to the contrary, the term "nucleotide" shall refer to ribonucleotides and deoxyribonucleotides.

[0083] The aptamer of the invention can comprise or consist of a DNA- or an RNA-nucleotide sequence and, thus, can be referred to as DNA-aptamer or RNA-aptamer, respectively. It is understood that, if the aptamer of the invention comprises an RNA-nucleotide sequence, within the sequence motifs specified throughout the present invention "T" stands for uracil.

[0084] For the sake of conciseness throughout the present invention, reference is made solely to explicit DNA-nucleotide sequences. However, it is understood that the respective RNA-nucleotide sequences are also comprised by the present invention.

[0085] According to one embodiment, the use of DNA-aptamers is preferred. DNA-aptamers are usually more stable in plasma than RNA-aptamers. However, according to an alternative embodiment, RNA-aptamers are preferred. According to another embodiment, single strand nucleotide sequences are preferred. According to another alternative embodiment, double strand nucleotide sequences are preferred.

[0086] The aptamers of the invention may comprise a nucleotide sequence containing 2'-modified nucleotides, e.g. 2'-fluoro-, 2'-methoxy-, 2'-methoxyethyl- and/or 2'-amino-modified nucleotides. The aptamer of the invention may also comprise a mixture of deoxyribonucleotides, modified deoxyribonucleotides, ribonucleotides and/or modified ribonucleotides. Respectively, the terms "2'-fluoro-modified nucleotide", "2'-methoxy-modified nucleotide", "2'-methoxyethyl-modified nucleotide" and/or "2'-amino-modified nucleotide" refer to modified ribonucleotides and modified deoxyribonucleotides.

[0087] The aptamer of the invention may comprise modifications. Such modifications encompass e.g. alkylation, i.e. methylation, arylation or acetylation of at least one nucleotide, the inclusion of enantiomers and/or the fusion of aptamers with one or more other nucleotides or nucleic acid sequences. Such modifications may comprise e.g. 5'- and/or 3'-PEG- or 5'- and/or 3'-CAP-

modifications. Alternatively or in addition, the aptamer of the invention may comprise modified nucleotides, preferably selected from locked-nucleic acids, 2'-fluoro-, 2'-methoxy- and/or 2'-amino-modified nucleotides.

[0088] Locked nucleic acids (LNA) represent analogons of the respective RNA nucleotides wherein the conformation has been fixed. Oligonucleotides of locked nucleic acids comprise one or more bicyclic ribonucleosides, wherein the 2'-OH group is connected with the C₄-carbon atom via a methylen group. Locked nucleic acids exhibit an improved stability versus nucleases compared to the respective unmodified RNA-aptamer counterparts. Also the hybridization properties are improved which allows for an enhancement of affinity and specificity of the aptamer.

[0089] Another preferred modification is the addition of a so called 3'-CAP-, a 5'-CAP-structure and/or of a modified guanosin-nucleotide (e.g. 7-methyl-guanosin) to the 3'- and/or 5'-end of the aptamer. Such a modification of the 3'- and/or 5'-end has the effect that the aptamer is protected from a fast degradation by nucleases.

[0090] Alternatively or in addition, the aptamer of the invention can exhibit a pegylated 3' or 5'-end. A 3'- or 5'-PEG modification comprises the addition of at least one polyethylene glycol (PEG) unit, preferably the PEG group comprises 1 to 900 ethylene groups, more preferably from 1 to 450 ethylene groups. In a preferred embodiment, the aptamer comprises linear PEG units with HO-(CH₂CH₂O)_n-H, wherein n is an integer of 1 to 900, preferably n is an integer of 1 to 450.

[0091] The aptamer of the invention can be wholly or in part configured as a peptide nucleic acid (PNA). The aptamers according to the present invention may further be modified as described in Keefe AD et al., Nat Rev Drug Discov. 2010 Jul;9(7):537-50 or in Mayer G, Angew Chem Int Ed Engl. 2009;48(15):2672-89 or in Mayer, G. and Famulok M., Pharmazie in unserer Zeit 2007; 36: 432-436.

[0092] The term "oligonucleotide" generally refers to a polynucleoside comprising a plurality of linked nucleoside units. Such oligonucleotides can be obtained from existing nucleic acid sources, including genomic or cDNA, but are preferably produced by synthetic methods. In preferred embodiments each nucleoside unit can encompass various chemical modifications and substitutions as compared to wild-type oligonucleotides, including but not limited to modified nucleoside base and/or modified sugar unit.

[0093] Examples of chemical modifications are known to the person skilled in the art and are described, for example, in Uhlmann, E. et al. (1990) Chem. Rev. 90:543; "Protocols for Oligonucleotides and Analogs" Synthesis and Properties & Synthesis and Analytical Techniques, S. Agrawal, Ed, Humana Press, Totowa, USA 1993; and Hunziker, J. et al. (1995) Mod. Syn. Methods 7:331-417; and Crooke, S. et al. (1996) Ann. Rev. Pharm. Tox. 36:107-129.

[0094] The nucleoside residues can be coupled to each other by any of the numerous known internucleoside linkages, inter alia to improve stability of the oligonucleotides against enzymatic degradation, e.g. by nucleases. Such internucleoside linkages include, without limitation, phosphodiester, phosphorothioate, phosphorodithioate, alkylphosphonate, alkylphosphonothioate, phosphotriester, phosphoramidate, siloxane, carbonate, carboalkoxy, acetamidate, carbamate, morpholino, borano, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphorothioate, and sulfone internucleoside linkages.

[0095] The term "oligonucleotide" also encompasses polynucleosides having one or more stereospecific internucleoside linkage (e.g., (*Rr*)- or (*Sr*)-phosphorothioate, alkylphosphonate, or phosphotriester linkages). As used herein, the terms "oligonucleotide" and "dinucleotide" are expressly intended to include polynucleosides and dinucleosides having any such internucleoside linkage, whether or not the linkage comprises a phosphate group. In certain preferred embodiments, these internucleoside linkages may be phosphodiester, phosphorothioate or phosphorodithioate linkages or combinations thereof, more preferably the internucleoside linkages are phosphorothioate.

[0096] Further, the aptamers may be encapsulated in suitable vehicles to protect their structural integrity as well as to promote their delivery inside cells. Preferred vehicles include liposomes, lipid vesicles, microparticles, and the like.

[0097] One advantage of modifying the aptamer of the invention by one of the ways mentioned above is that the aptamer can be stabilized against detrimental influences like e.g. nucleases present in the environment wherein the aptamer is used. Said modifications are also suitable to adapt the pharmacological properties of the aptamer. The modifications preferably do not alter the affinity or specificity of the aptamer.

[0098] The aptamer of the invention may also be conjugated to a carrier molecule and/or to a reporter molecule. Carrier molecules comprise such molecules that, when conjugated to the aptamer, prolong the plasma half-life of the conjugated aptamer in human plasma, e.g. by enhancing the stability and/or by affecting the excretion rate. One example of a suitable carrier molecule is PEG.

[0099] Reporter molecules comprise molecules that allow for the detection of the conjugated aptamer. Examples of such reporter molecules are GFP, biotin, cholesterol, dyes like e.g. fluorescence dyes, electrochemically active reporter molecules and/or compounds comprising radioactive residues, in particular radionuclides suitable for PET (positron emission tomography) detection like e.g. ^{18}F , ^{11}C , ^{13}N , ^{15}O , ^{82}Rb or ^{68}Ga . The skilled person is well aware of suitable carrier and reporter molecules and of ways of how to conjugate them to the aptamer of the invention.

[0100] In one preferred embodiment of the first aspect of the invention, the aptamer of the invention has anticoagulant activity. Anticoagulant activity may preferably mean antithrombotic activity and preferably be understood as preventing or reducing microthromboses.

[0101] More preferably the aptamer of the invention is able to prolong coagulation time measured as partial thromboplastin time (PTT or alternatively aPTT) of human calibration plasma to 60 seconds or more at an aptamer concentration of 0.03 mg/ml. According to one embodiment of the present invention, the aptamer of the invention is able to prolong coagulation time measured as partial thromboplastin time of human calibration plasma to 40 seconds or more, more preferably to 50 seconds or more at an aptamer concentration of 0.03 mg/ml. According to one preferred embodiment, the aptamer of the present invention prolongs partial thromboplastin time of human calibration plasma more than aptamer AS1411 (SEQ ID NO: 7).

[0102] Also more preferably, the aptamer is able to lower the prothrombin time (Quick value) of human calibration plasma to 40% or less at an aptamer concentration of 0.03 mg/ml. According to one embodiment of the present invention, the aptamer of the invention is able to lower the

prothrombin time (Quick value) of human calibration plasma to 80% or less, more preferably to 70% or less, even more preferably to 60% or less, particularly preferably to 50% or less at an aptamer concentration of 0.03 mg/ml. According to one preferred embodiment, the aptamer of the present invention lowers the prothrombin time (Quick value) of human calibration plasma more than aptamer AS1411 (SEQ ID NO: 7).

[0103] According to one preferred embodiment, the PTT time is assessed by using the test described in the Examples section hereinbelow. Alternatively preferably, the PTT time and/or the Quick value is assessed as commonly known in the art. As calibration plasma, any human reference plasma of a healthy individual may be used, preferably HemosIL human calibration plasma (Instrumentation Laboratory, Werfen) is employed.

[0104] In another preferred embodiment of the first aspect of the invention, the aptamer selectively interacts with or binds to human thrombin, preferably the K_D value for binding of the aptamer to human thrombin is 1 μ M or less, more preferably the K_D value is 100 nM or less, even more preferably the K_D value is 10 nM or less. K_D values may preferably be determined using a dilution series of human thrombin (ranging between 1 pM and 1000 nM) in the dot blot binding assay and fitting an equation describing a 1:1 NA:protein complex to the resulting data (fraction aptamer bound = $\text{amplitude} * ([\text{Thrombin}] / (K_D + [\text{Thrombin}]))$) (KaleidaGraph v. 3.51, Synergy Software, Reading, Pa.).

[0105] Within the present invention, selective binding or interaction or specific binding or interaction between two molecules may preferably mean that the two cited molecules bind or interact with an at least 10-fold, more preferably at least 50-fold, particularly preferably at least 100-fold increased affinity compared to unrelated, non-interacting or non-binding molecules as binding partners.

[0106] The aptamers of the present invention are useful for the treatment of infections with virus strains from the *Coronaviridae* family. In the context of the present invention, the aptamers are considered to be useful for human subjects as well as for animal subjects. According to one embodiment, the aptamers are for use in human subjects. According to another embodiment, the aptamers are for use in animal subjects.

[0107] By inhibiting infection with a Coronavirus, the potentially negative effects of Coronavirus infection are neutralized and diminished and any disease symptom may be abolished or reduced to normal levels. As a consequence, the extent and gravity of a disease caused or associated with Coronavirus infection may be significantly reduced. Thus, the present invention provides aptamers that are suitable for use in treatment of diseases or symptoms associated with Coronavirus infection.

[0108] According to another embodiment of the present invention, a method of preventing infection of somatic cells with a virus from the *Coronaviridae* family is provided by using an aptamer according to the present invention. In one preferred embodiment, the method of preventing infection encompasses treating, curing or preventing progression of infection with a virus from the *Coronaviridae* family in a subject.

[0109] In a preferred embodiment of the present invention, the method is carried out *in vitro/ex vivo*. More preferably, the cell to be contacted with an aptamer according to the method of the present

invention does not form part of a whole living organism. In one embodiment, the cell to be contacted may be cultured in cell culture. Such cultures of individual or groups of cells may be carried out as usually done in the art.

[0110] In another preferred embodiment of the method of the present invention, the method may be carried out *in vivo* and/or on cells which form part of a whole living organism. According to this embodiment, the cells, tissue or organ to be contacted has/have previously been diagnosed as being infected with a virus from the *Coronaviridae* family. Preferably, the cells to be treated according to the present invention belong to the gastrointestinal or respiratory tracts, more preferably to the respiratory tract, more preferably lung cells are treated.

[0111] The present invention is also directed to an aptamer for use in therapy of a subject by treating, curing or preventing disease symptoms associated with long COVID in a patient having overcome an infection with a virus from the *Coronaviridae* family, wherein the aptamer comprises a nucleic acid sequence of SEQ ID No. 1 (GGT TGG TGT GGT TGG) and/or a nucleic acid sequence being at least 80% identical to SEQ ID No. 1.

[0112] Long COVID is a condition or a complex of symptoms which has been observed in patients which have overcome an infection with a virus from the *Coronaviridae* family. While the complex of symptoms associated therewith is still under examination, it becomes more and more evident that symptoms prevail even after disappearance of symptoms of an active infection.

[0113] Based on experimental data also included herein, it became evident that numerous of these observed symptoms in patients having endured an active SARS-CoV-2 infection have an association with the presence of functional autoantibodies (Figure 10). Since it was previously demonstrated that the aptamers of the present invention have inhibitory activity against such functional autoantibodies (also demonstrated in Figure 11 herein), the inventive aptamers can be assumed to have activity against such symptoms grouped together as Long COVID.

[0114] In any case, the symptoms summarized as Long COVID herein are considered to be late effects or delayed effects of an infection with *Coronaviridae* such as SARS-CoV-2. In this regard, the special effects of the aptamers of the invention on Long COVID may be seen as part of treating infection with a virus from the *Coronaviridae* family, such as SARS-CoV-2, as described and claimed herein.

[0115] In one embodiment, the disease symptoms comprise one or more from the group comprising neurological symptoms, such as chronic fatigue syndrome, postural orthostatic tachycardia syndrome (PoTS), dysautonomia, tremor, attention deficit, anomie aphasia, neuropathy, transverse myelitis, acute necrotising myelitis, and Guillain-Barré syndrome, cardiovascular symptoms, such as myocardial inflammation, arrhythmia, tachycardia, bradycardia, hypertension, and atrioventricular (AV) block, dermatological symptoms, such as alopecia and eczema, or gastrointestinal diseases.

[0116] Preferably, the aptamer is used to inhibit the interaction of autoantibodies specific for a G-protein coupled receptor with its target proteins. Also preferably, the aptamer is for use in the treatment of a patient in which autoantibodies against G-protein coupled receptors can be detected.

[0117] In one embodiment of the present invention, the patient to be treated exhibits functional

autoantibodies against G-protein coupled receptors, preferably functional autoantibodies specific for any one of the human G-protein coupled receptor adrenergic alpha-1 receptor, adrenergic beta-2 receptor, endothelin 1 ETA receptor, muscarinic M2 receptor, angiotensin II AT1 receptor, MAS-receptor and/or the nociception receptor, more preferably for any one of the adrenergic beta-2 receptor, muscarinic M2 receptor, angiotensin II AT1 receptor, MAS-receptor, particularly preferably wherein the patient exhibits an antibody pattern comprising functional autoantibodies specific for each of the adrenergic beta-2 receptor, muscarinic M2 receptor, angiotensin II AT1 receptor, and MAS-receptor.

[0118] The present invention is also directed to a pharmaceutical composition comprising at least one aptamer of the invention and, optionally, at least one pharmaceutically acceptable excipient. The invention is also directed to a pharmaceutical composition comprising an aptamer of the invention or a mixture of different aptamers of the invention and a pharmaceutically acceptable excipient like e.g. a suitable carrier or diluent.

[0119] Preferably, the aptamer of the invention constitutes an active ingredient of the pharmaceutical composition and/or is present in an effective amount. The term "effective amount" denotes an amount of the aptamer of the invention having a prophylactically, diagnostically or therapeutically relevant effect on a disease or pathological condition. A prophylactic effect prevents the outbreak of a disease. A therapeutically relevant effect relieves to some extent one or more symptoms of a disease or returns to normal either partially or completely one or more physiological or biochemical parameters associated with or causative of the disease or pathological conditions.

[0120] The respective amount for administering the aptamer of the invention is sufficiently high in order to achieve the desired prophylactic, diagnostic or therapeutic effect. It will be understood by the skilled person that the specific dose level, frequency and period of administration to any particular mammal will depend upon a variety of factors including the activity of the specific components employed, the age, body weight, general health, sex, diet, time of administration, route of administration, drug combination, and the severity of the specific therapy. Using well-known means and methods, the exact amount can be determined by one of skill in the art as a matter of routine experimentation.

[0121] According to one embodiment of the pharmaceutical composition of the invention, at least 20% of the total aptamer content is made of an aptamer of the invention, preferably at least 50%, more preferably at least 75%, most preferable at least 95%.

[0122] When used for therapy, the pharmaceutical composition will generally be administered as a formulation optionally in association with one or more pharmaceutically acceptable excipients. The term "excipient" is used herein to describe any ingredient other than the aptamer of the invention. The choice of excipient will to a large extent depend on the particular mode of administration. Excipients can be suitable carriers and/or diluents.

[0123] The pharmaceutical composition of the invention may preferably be administered orally or intravenously. According to one preferred embodiment, the pharmaceutical composition is administered by inhalation. According to an alternative embodiment, the pharmaceutical composition is administered intravenously.

[0124] According to a preferred embodiment, the pharmaceutical composition is administered to the subject by systemic delivery or pulmonary delivery, preferably by pulmonary delivery, more preferably by inhalation. The pharmaceutical composition to be administered by inhalation may preferably be in the form of a powder or a spray.

[0125] For administration to human patients, the total daily dose of the aptamer of the invention and/or the pharmaceutical composition of the invention is typically in the range 0.001 mg to 8000 mg depending, of course, on the mode of administration. For example, an intravenous daily dose may only require from 0.001 mg to 40 mg. The total daily dose may be administered in single or divided doses and may, at the physician's discretion, fall outside of the typical range given herein.

[0126] These dosages are based on an average human subject having a weight of about 75 kg to 80 kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.

[0127] In the context of the present invention, the aptamer may preferably be administered in combination with one or more vaccines, antigens, antibodies, cytotoxic agents, allergens, antibiotics, antisense oligonucleotides, TLR antagonist, peptides, proteins, gene therapy vectors, DNA vaccines, adjuvants, kinase inhibitors, T-cell therapeutics or sulphated polyglycerols or similar sulphated polymers.

[0128] The present invention also encompasses a kit comprising an aptamer of the invention, a container and optionally written instructions for use and/or with means for administration.

[0129] For treatment of a disease caused or associated with an infection with a Coronavirus, irrespective of the route of administration, the aptamer of the invention is administered at an overall daily dose per treatment cycle of not more than 150 mg/kg body weight, preferably of not more than 20 mg/kg body weight, more preferably of not more than 10 mg/kg body weight, even more preferably selected from the range of 1 µg/kg to 20 mg/kg body weight, most preferably selected from a range of 0.01 to 10 mg/kg body weight. In a preferred embodiment of the present invention, the aptamer is administered in multiple separate dosage steps over the course of one day, preferably between 2 and 6 times per day, for example 4 times a day. The aptamer may be administered in four doses of 1900 mg each per day.

[0130] According to one aspect of the present invention, the use of the aptamer as defined herein is provided for preventing infection of somatic cells with a virus from the *Coronaviridae* family. In a preferred embodiment of the present invention, the aptamer may be used *in vitro/ex vivo*. In an alternative preferred embodiment, the aptamer may be used *in vivo*.

[0131] The manufacturing or mass production of aptamers of the invention is well known in the art and represents a mere routine activity.

[0132] According to one aspect of the present invention, affinity molecules are provided that specifically bind to a peptide of amino acid sequence Leu-Tyr-Arg-Asn-Arg-Asp-Val (LYRNRDV; SEQ ID NO: 9) and/or His-Arg-Phe-Tyr-Arg-Leu-Ala-Asn (HRFYRLAN; SEQ ID NO: 10) of the RNA-dependent RNA polymerase of the Severe acute respiratory syndrome coronavirus 2 (SEQ ID NO: 8).

[0133] Within the present invention, an affinity molecule may be any molecule with high affinity to a given target, e.g. to the peptides of SEQ ID NO: 9 or 10. Binding with high affinity preferably means binding to said target epitopes with an at least 10-fold, preferably at least 50-fold, more preferably at least 100-fold increased affinity compared to unrelated epitopes, proteins or protein regions.

[0134] In additional studies carried out by the inventors, it was surprisingly found that the claimed aptamer specifically interacts and binds to two previously unknown, distinct epitopes of the enzyme RNA-dependent RNA polymerase of SARS-CoV-2 (SEQ ID NO: 8; NCBI Reference Sequence Accession Number: YP_009725307.1). By way of NMR studies as well as isothermal titration calorimetry, selective interaction between the aptamer of the present invention and said epitopes of the RNA-dependent RNA polymerase have been conclusively shown (see Figures 6 and 7). The defined peptide stretches of this enzyme against which specific binding was observed are amino acids 731 to 737 (LYRNRDV; SEQ ID NO: 9) and amino acids 650 to 657 (HRFYRLAN; SEQ ID NO: 10).

[0135] Equivalent target sequences have also been identified in the sequence of RNA-dependent RNA polymerase from another member of the *Coronaviridae* family, SARS-CoV (data not shown). It is known from the prior art that the sequences of RNA-dependent RNA polymerases share very high amino acid sequence identity within the *Coronaviridae* family, but has very low sequence similarity to other viral RNA-dependent RNA polymerases and Reverse Transcriptases (cf., for example, Xu X et al. (2003) Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. *Nucleic Acids Res* 31:7117-7130, page 7118, right-hand column, 1st full paragraph, 2nd sentence). Therefore, it can be plausibly assumed that equivalent target sequences are also present in the RNA-dependent RNA polymerase of other viruses of the *Coronaviridae* family.

[0136] Such strong interaction as observed in NMR studies is also in this case highly plausible and likely to persist in the full-length molecule as well as in active viruses of the *Coronaviridae* family. In fact, the additional activity of the claimed aptamer against the Spike protein as well as against the viral RNA-dependent RNA polymerase could explain the superior results observed in the cell culture assay in comparison to known drugs.

[0137] While it was previously reported that antiviral agents active against *Coronaviridae* such as Remdesivir and Galidesivir may interact with sequences within the RNA-dependent RNA polymerase (cf. Wang Y, Anirudhan V, Du R, Cui Q, and Rong L (2020) RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target. *J Med Virol*, doi: 10.1002/jmv.26264. for studies with Galidesivir and the identification of amino acids Thr455, Arg553, Lys621, Arg624, Asp452, Ala554, Asp623, Asn691, Ser759, Asp760 as target amino acids, and Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, Wang Q, Xu Y, Li M, Li X, Zheng M, Chen L, and Li H (2020) Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharm Sin* 8, doi: 10.1016/j.apsb.2020.02.008. for studies with Remdesivir and the identification of amino acids Asn 497, Arg 569, Asp 684, Leu 576, Ala 685, Tyr 687 as target amino acids), the reported sequences are distinct from and unrelated to the peptide stretches identified by the present inventors.

[0138] The target enzyme RNA-dependent RNA polymerase is a key component of the viral replication machinery of *Coronaviridae* viruses. It will be apparent to the skilled person that specific binding of or to such an enzyme will at least interfere with, impair or even inhibit correct and efficient replication of viral RNA of the RNA viruses of the *Coronaviridae* family. In this way, the infectivity of

the virus will be reduced due to an impact on the life cycle of the virus in its host.

[0139] The identification of novel epitopes of said key enzyme is a significant contribution to the technical field, since it will allow the generation and identification of additional binding partners also leading to interference with or inhibition of viral replication. Also, since the newly identified epitopes are distinct from any epitopes of said key enzyme previously known as suitable binding sites for affinity molecules, any affinity molecule binding thereto will at least act to supplement the inhibitory action provided by any other molecule specifically binding to RNA-dependent RNA polymerase.

[0140] It was additionally recognized and demonstrated that the newly identified epitopes are positioned towards the outside of the enzyme, thus facing the solvent and being easily accessible for specific interaction or binding (data not shown). It should also be mentioned that aptamer binders are in most cases able to interfere with the functionality of their target proteins and are even deliberately expressed for this purpose *in vivo* (Ulrich H (2005) DNA and RNA aptamers as modulators of protein function. Medicinal Chemistry (Sharjah (United Arab Emirates)) 1:199-208.).

[0141] Surprisingly, the aptamer of the present invention not only demonstrated a very efficient inhibition of the viral activity of SARS-CoV-2 but actually appeared to surpass other antiviral agents currently discussed as potential therapeutic options for COVID-19 (see Example 2). This may be due to the dual action on the virus infection process as well as on its replication in the host.

[0142] By providing new epitopes of this key enzyme which is crucial for the replication cycle of the virus, the skilled person will be able to identify, raise or generate additional small molecules, antibodies or antibody-derived biologics, or oligonucleotides/aptamers with affinity to said newly identified epitopes by using standard procedures as commonly known in the art.

[0143] In a preferred embodiment of the sixth aspect of the present invention, the affinity molecule is a small molecule having a molecular weight of at most 900 Daltons. Preferably the affinity molecule is a small molecule from any one small molecule collection from the group comprising the University of Cincinnati Compound Collection, the DiscoveryProbe™ Bioactive Compound Library Plus from ApexBio Technology LLC, and the SARS-CoV-2 Screening Library from Cayman Chemical.

[0144] According to one preferred embodiment of the present invention, the affinity molecule is a small molecule present in the ZINC 15 database (Sterling T and Irwin JJ, Journal of Chemical Information and Modeling 2015 55 (11), 2324-2337; DOI: 10.1021/acs.jcim.5b00559).

[0145] Alternatively preferably, the affinity molecule is found to have potential activity against at least one viral target, more preferably at least two viral targets according to the disclosure of Kowalewski J and Ray A (2020), Heliyon. 6. e04639. 10.1016/j.heliyon.2020.e04639.

[0146] With respect to COVID-19 inhibition, previous publications already screened existing drug or small molecule libraries and checked for possible interaction/binding with proteins crucial for SARS-CoV-2 infection or replication, exploiting *inter alia* appropriate *in silico* methods (computer programs) which are able to identify such interaction.

[0147] In such screens, existing drugs were screened for potential binding to known protein structures of SARS-CoV-2, thereby identifying, besides known virustatic agents, the anti-ulcer drug,

Famotidine, as a possible 3CLpro-protease blocker of SARS-CoV-2 (Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, Wang Q, Xu Y, Li M, Li X, Zheng M, Chen L, and Li H (2020) Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharm Sin B*, doi: 10.1016/j.apsb.2020.02.008.) and several antibiotics as possible blockers of the RNA-dependent RNA polymerase (Pokhrel R, Chapagain P, and Siltberg-Liberles J (2020) Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2. *J Med Microbiol*, doi: 10.1099/jmm.0.001203.) as also other small molecules as blockers of the RNA-dependent RNA polymerase (Aftab SO, Ghouri MZ, Masood MU, Haider Z, Khan Z, Ahmad A, and Munawar N (2020) Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach. *Journal of Translational Medicine* 18:275.).

[0148] Along the same lines, the skilled person would be able to take any available collection or library of small molecules, either as bulk library or sub-grouped by specific affinities, features or requirements, and run high-throughput analyses, e.g. based on surface plasmon resonance, against any of the newly identified peptide epitopes of SEQ ID NO: 9 or 10 as targets. In so doing, novel small molecules exhibiting specific binding to the new epitopes can be identified without an undue burden and using standard procedures commonly known in the art.

[0149] Exemplary collections of small molecules which may preferably be used are the ChemBridge DIVERSet-CL and -EXP collections from ChemBridge Corporation, San Diego, CA, USA, the Maybridge Screening Collection (in the form of Maybridge HitDiscover, Maybridge HitFinder or Maybridge HitCreator) from Thermo Fisher Scientific, Geel, Belgium, the Antiviral Screening Library (Supplier/Item Nr. 30390-50) or the SARS-CoV-2 Screening Library (Supplier/Item Nr. 9003509) from Cayman Chemical, Ann Arbor, MI, USA, or any Diversity Set of University of Cincinnati Compound Collections, or any other available collection or library of suitable small molecules as deemed useful by a skilled person.

[0150] In another preferred embodiment of the sixth aspect of the present invention, the affinity molecule is a peptide-based compound, more preferably an antibody or a binding fragment thereof.

[0151] In order to raise novel antibodies or binding fragments of such antibodies, it is easy, straightforward and common practice to generate effective monoclonal antibodies by using the established and reliable hybridoma technology against the newly identified peptide epitopes. while e.g. immunizing an animal with the corresponding peptide sequence. While it is probable that for the treatment of a viral disease not the full antibody (about 150 kDa) will be administered, fragments such as e.g. Fab-fragments or even smaller parts derived from an antibody may be used for therapy, in order to be able to reach the target *in vivo*.

[0152] Such binding fragments may consist of or comprise Fab, Fab', Fab'-SH, F(ab)₂, Fv, a diabody, single chain antibody fragment or other fragments having the specific affinity to the epitope. In this regard, within the present invention, an affinity molecule specifically binding to or directed against the newly found epitopes of SEQ ID NO: 9 or 10 means an affinity molecule binding to said target epitopes with an at least 10-fold, preferably at least 50-fold, more preferably at least 100-fold increased affinity compared to unrelated epitopes, proteins or protein regions.

[0153] According to a preferred embodiment of the present invention, specific binding of an affinity molecule to the isolated target epitopes is considered to be given at a K_D of less than 500 μM,

preferably less than 200 μM , more preferably less than 100 μM , when measured by isothermal titration calorimetry as further described below. According to another preferred embodiment of the present invention, specific binding of an affinity molecule to the full-length RNA-dependent RNA polymerase is considered to be given at a K_D of less than 1 mM, preferably less than 100 μM , more preferably less than 10 μM , when measured by isothermal titration calorimetry as further described below. Alternatively preferably, affinity measurements for determination of K_D values may be carried out using the Biacore[™] assay from GE Healthcare Life Sciences according to the Biacore Assay Handbook 29-0194-00 Edition AA, or any other affinity measurement as known in the art.

[0154] In one other preferred embodiment of the sixth aspect of the present invention, the affinity molecule is an aptamer or oligonucleotide. As is the case for antibodies, there are procedures to generate specifically binding oligonucleotide molecules to targets which are accessibly and can easily be employed in such assays.

[0155] SELEX as one of these technologies for finding novel oligonucleotide binders to a known epitope was used and described as early as 1990. Today, many different SELEX-based aptamer selection procedures are developed and are in use (Ali MH, Elsherbiny ME, and Emara M (2019) Updates on Aptamer Research. International Journal of Molecular Sciences 20.) which altogether enabled the selection of aptamers to almost all thinkable targets (Stoltenburg R, Nikolaus N, and Strehlitz B (2012) Capture-SELEX: Selection of DNA Aptamers for Aminoglycoside Antibiotics. Journal of Analytical Methods in Chemistry 2012:415697.).

[0156] Since the first publication of aptamers in 1990, aptamers have been described for a wide variety of different classes of targets from small molecules, like nucleotides, cofactors or amino acids, over peptides, polysaccharides and proteins to complex structures like whole cells, viruses and single cell organisms (cf. for example Zhang Y, Lai BS, and Juhas M (2019) Recent Advances in Aptamer Discovery and Applications. Molecules 24.).

[0157] In this regard, the provision of novel epitopes within a key enzyme of *Coronaviridae* viruses enables the skilled person to generate additional affinity molecules such as small molecules, antibody-derived compounds as well as aptamers by using standard procedures as commonly known in the art. Such additional affinity molecules are considered plausible active agents for fighting infection with SARS-CoV-2 due to their specific binding to a yet unknown site within a key enzyme of the virus, thus interfering with the viral replication cycle.

[0158] All embodiments of the present invention as described herein are deemed to be combinable in any combination, unless the skilled person considers such a combination to not make any technical sense.

Examples

1. NMR analysis of the interaction between BC007 and a sequence motif of the Receptor-binding domain (RBD) of SARS-CoV-2

[0159] All NMR spectra were acquired at 600 MHz on a Bruker AV600 spectrometer (Bruker Biospin, Rheinstetten, Germany) in 90/10 H₂O/D₂O at 298K. The solvent signal was suppressed using Watergate w5 pulse sequence included in the Bruker pulse program zgpgw5. Acquisition parameters included: time domain = 65K, number of scans = 512, sweep width = 24 ppm and 90° high power pulse = 13.8 µs.

[0160] The concentration of BC007 and the peptide of SEQ ID NO: 5 was 1mM. Substances were dissolved in 0.5ml pure H₂O/D₂O mixture without any additives.

[0161] The upper NMR spectrum in Figure 1 of BC007 in combination with the peptide of SEQ ID NO: 5 from the Receptor-binding domain of the Spike protein from SARS-CoV-2 (upper spectrum) shows formation of the quadruplex structure of BC007 induced by interaction with the peptide and clearly recognizable by eight imino signals at 12.5 ppm; the peptide signals in the spectrum are strongly shifted and broadened in comparison to the potassium-induced fold, an effect that is caused by the interaction of the two molecules (peptide with BC007).

[0162] In the lower NMR spectrum in Figure 1, the imino signals in the range of 12 ppm are again a clear indication of the structure formation induced by the presence of potassium ions, the chemical shifts of the imino protons however clearly differ from those of the upper spectrum. No imino signals in the range of 12 ppm are observed for the peptide alone (middle spectrum).

[0163] The aptamer of SEQ ID NO: 1 has previously been reported to be stabilized in its characteristic fold in the presence of potassium ions (Schultze, P. et al., 1994. Three-dimensional solution structure of the thrombin-binding DNA aptamer d(GGTTGGTGTGGTTGG). J. Mol. Biol. 235, 1532-1547. <https://doi.org/10.1006/jmbi.1994.1105>) and to be present in a predominantly random coil structure in water (cf. Weisshoff, H. et al., 2018. Characterization of Aptamer BC 007 Substance and Product Using Circular Dichroism and Nuclear Magnetic Resonance Spectroscopy. J Pharm Sci. <https://doi.org/10.1016/j.xphs.2018.04.003>).

[0164] In the enlarged view of Figure 2, it can be seen how the peaks present for each molecule alone are based on very sharp signals. These signals are then broadened and shifted in their position in the upper spectrum due to the strong interaction between the aptamer of SEQ ID NO: 1 as the agent thought to be active against Coronavirus and SEQ ID NO: 5 as a representative sequence from the Receptor-binding domain of the Spike protein of SARS-CoV-2.

[0165] Based on these results, it is expected that said interaction also occurs under in vivo conditions, with the complete virus material and other strains of the same family of *Coronaviridae* which also use Spike proteins and their Receptor-binding domains for cell entry and infection.

2. Inhibition of SARS-CoV-2 replication by BC 007 in human and primate cell lines

[0166] Investigation of the antiviral dose-response effect of BC 007 was carried out in VeroFM and Calu-3 cells. The aptamer BC 007 of SEQ ID No. 1 was added to the virus at different concentrations and kept for 15 min at 4° C, before the mixture was added onto the cells (to a MOI 0.0005) and warmed up to 37° C for 30 min in order to start virus attachment and entry.

[0167] After this 30 min incubation, supernatants were removed, cells were washed once with PBS and medium containing the same final concentration of BC 007 was added after washing. After an incubation of 24 hrs at 37° C (replication), a sample aliquot for each concentration was taken for the plaque assay which was carried out as described previously (Herzog et al., Virology Journal 2008, 5:138).

[0168] BC007 demonstrated highly efficient inhibition of virus replication at low doses in Vero as well as Calu-3 cell lines (see Figure 3). Half-maximal effective concentrations (EC₅₀, alternatively termed half-maximal inhibitory concentration IC₅₀) determined for inhibition of viral infection of were at 3,74 µM for Calu-3 cells and 0.21 µM for Vero cells.

[0169] For a comparison to other antiviral agents implicated for potential treatment of SARS-CoV-2, reference is made to the publication of Wang et al., Cell Research 2020, 30:269-271. Therein, ribavirin, penciclovir, favipiravir, nitazoxanide, chloroquine and remdesivir were tested in a similar experimental setup using Vero E6 cells and a starting MOI of 0.05.

[0170] In this report of Wang et al., the EC₅₀ concentrations were determined as 109.50 µM for ribavirin, 95.96 µM for penciclovir, 61.88 µM for favipiravir, 2.12 µM for nitazoxanide, 1.13 µM for chloroquine and 0.77 µM for remdesivir (see full paragraph bridging left-hand column and right-hand column on page 269 and Figure 1a on page 270 of Wang et al., 2020).

[0171] Based on the results obtained with remdesivir, it was concluded that remdesivir potently blocked virus infection at low-micromolar concentration. Further, remdesivir lacked substantial cell-toxicity at the concentrations used for testing its SARS-CoV-2 inhibiting effect.

[0172] In view of the results reported in Wang et al., 2020, it becomes clear that the results obtained in Vero cells with the aptamer of the present invention also demonstrate potent blockage of virus infection up to or even beyond the efficiency observed with other antiviral agents currently discussed as potential treatment options for *Coronaviridae* infections.

[0173] Importantly, and in analogy to the molecules identified to perform very well in Wang et al., 2020, the aptamer of the present invention not only showed efficient inhibition of infectious activity of SARS-CoV-2 on Vero and moreover also on human cells (Calu-3), but also lacked any toxicity as already shown in a successfully completed phase I of clinical testing (Becker et al., Clin Drug Investig 2020 May;40(5):433-447) at the doses intended and required for the observed inhibition of SARS-CoV-2 in human cells.

[0174] The striking advantage of the aptamer of the present invention over remdesivir as a presently discussed treatment option is the simplicity and ease of preparation of said aptamer. Remdesivir as an example for antiviral agents suggested for treatment of *Coronaviridae* infections had been reported as requiring about 70 raw materials, reagents and catalysts, some of which are highly dangerous to human (cf. Langreth, Robert (14 May 2020). "All Eyes on Gilead". Bloomberg Businessweek. Bloomberg, L.P.).

[0175] Furthermore, the synthesis apparently involves approximately 25 time-consuming chemical steps leading to a required time for the original end-to-end manufacturing process of 9 to 12 months

to go from raw materials at contract manufacturers to the finished product.

[0176] In contrast, the aptamer of the present invention which may be used and administered as an unmodified DNA molecule can be produced on a large scale up to kilogram amounts satisfying global needs in a matter of weeks for a fraction of the costs involved for comparative antiviral agents such as remdesivir.

3. Interaction between BC007 and human thrombin and consequent inhibition of coagulation

[0177] Human thrombin (250 nM) is immobilized with 0,1 M carbonate buffer overnight at 4°C on Nunc Maxisorp ELISA-plates and then blocking is carried out with 1% BSA in phosphate buffered saline solution (PBS), pH 7,4, for 1 hr at room temperature. Then, 5'-biotinylated aptamer BC007 is added in various concentrations (100 nM, 500 nM und 1000 nM) and incubated for 2 hours at room temperature. Aptamer bound to thrombin is detected via POD-coupled Neutravidine, wherein the amount of POD is determined via hydrogen peroxide/tetramethylbenzidine (TMB) reaction and readout is performed with a plate reader at a wavelength of 450 nm = measuring wave length (650 nm reference wave length). Washing is carried out between each using routine ELISA-washing buffer; thrombin-free plastic plates serve as controls. Results of the thrombin binding assay are shown in Figure 4.

[0178] For the determination of coagulation inhibition, partial thromboplastin time (PTT) was measured as follows. 50 µl of a 1 mM aptamer solution (BC007 of SEQ ID NO:1 or aptamer AS1411 of SEQ ID NO: 7 as reference aptamer) was diluted in 1mL HemosIL human calibration plasma ((Instrumentation Laboratory, Werfen). This solution was then further serially diluted 1:2 to concentrations of 0.083, 0.028, 0.009, 0.003, 0.001 mg/ml in HemosIL calibration plasma.

[0179] These samples were incubated with phospholipids and buffer according to the manufacturer's protocol. After the addition of calcium, the time to coagulation was measured with an ACL TOP Coagulation system (Werfen). Results are shown in Figure 5A.

[0180] Quick values of aptamer BC007 and reference aptamer AS1411 of SEQ ID NO: 7 were determined as commonly known in the art. Results are shown in Figure 5B (Quick value).

4. Analysis of the interaction between BC007 and two sequence motifs of the RNA-dependent RNA polymerase of SARS-CoV-2

[0181] Two sequence sections taken from RNA-dependent RNA polymerase of Severe acute respiratory syndrome coronavirus 2 (NCBI Reference Sequence: **YP_009725307.1**): HRFYRLAN (His⁶⁵⁰-Arg⁶⁵¹-Phe⁶⁵²-Tyr⁶⁵³-Arg⁶⁵⁴-Leu⁶⁵⁵-Ala⁶⁵⁶-Asn⁶⁵⁷) and LYRNRDV (Leu⁷³¹-Tyr⁷³²-Arg⁷³³-Asn⁷³⁴-Arg⁷³⁵-Asp⁷³⁶-Val⁷³⁷) were analysed for binding and interaction with BC007 via NMR-spectroscopy. Both sequence sections (peptides) were able to force BC 007 into its well-known quadruple structure (**Figure 6**), which is the readout for successful and specific binding.

[0182] The upper NMR spectrum of BC 007 in combination with LYRNRDV in the upper part of Figure

6 shows formation of the quadruplex structure of BC 007 induced by molecular interaction with the peptide which is clearly recognisable by the imino signals between 11.5 and 12.5 ppm. The lower spectrum shows the binding between BC 007 and HRFYRLAN.

[0183] Substances were dissolved in 0.5 ml pure H₂O/D₂O mixture without any additives. The NMR data investigating the interaction of BC 007 with these sequence-sections of SARS-CoV-2 proteins were acquired at 600 MHz on a Bruker AV600 spectrometer (Bruker Biospin, Rheinstetten, Germany) in 90/10 H₂O/D₂O at 298K. The solvent signal was suppressed using the Watergate w5 pulse sequence included in the Bruker pulse program zgpgw5. Acquisition parameters included: time domain = 65K, number of scans = 512, sweep width = 24 ppm and 90° high power pulse = 13.8 µs.

[0184] Further analysis of the binding between HRFYRLAN and BC007 was performed by isothermal titration calorimetry (ITC). The results of this ITC analysis are shown in **Figure 7**, wherein the thermogram is in the upper part and the binding isotherm in the lower part.

[0185] The ITC experiments were performed on MicroCal PEAQ-ITC microcalorimeter (Malvern Panalytical GmbH, Germany). Both interaction partners were solved in 50 mM sodium phosphate, 150 mM NaCl buffer, pH 7.06. Experiments were carried out at 25° C. In routine experiments, peptide (3.6 or 4 mM) was titrated in 2µl-steps into aptamer solution (200µM) in the calorimeter cell. Time intervals between the injections were adjusted to 200 sec, which was sufficient for the heat signal to return to baseline. Reaction mixtures were continuously stirred at 750 rpm.

[0186] Dilution heats associated with the addition of the peptides into buffer (determined in separate control experiments) had small constant values that were negligible to measured binding heats. The instrument software (MicroCal PEAQ-ITC Analysis) was used for baseline adjustment, peak integration and normalization of the reaction heats with respect to the molar amount of injected ligand as well as for data fitting and binding parameter evaluation.

[0187] This ITC analysis revealed a 1:1 stoichiometric binding between the two binding partners BC007 and HRFYRLAN which strongly supports a true and specific binding.

[0188] A control experiment for the ITC analysis was run using a highly charged peptide from the Spike RBD of SARS-CoV-2 having the sequence NRKRISN (SEQ ID NO:11; theoretical pI value of 12.01) . The results are shown in **Figure 8**. With this control, a sole non-specific electrostatic interaction between the binding peptides of the RNA-dependent RNA polymerase HRFYRLAN (theoretical pI value of 10.84) and LYRNRDV (theoretical pI value of 8.75) and BC 007 could clearly have been excluded.

[0189] The experiments were again performed on MicroCal PEAQ-ITC microcalorimeter (Malvern Panalytical GmbH, Germany). Both interaction partners were solved in 50 mM sodium phosphate, 150 mM NaCl buffer, pH 7.16. Experiments were carried out at 25° C. In routine experiments, peptide (3.6 or 4 mM) was titrated in 2µl-steps into aptamer solution (200µM) in the calorimeter cell. Time intervals between the injections were adjusted to 200 sec, which was sufficient for the heat signal to return to baseline. Reaction mixtures were continuously stirred at 750 rpm. Dilution heats associated with the peptides-addition into buffer (determined in separate control experiments) had small constant values that were negligible to measured binding heats. The instrument software (MicroCal PEAQ-ITC Analysis) was used for baseline adjustment, peak integration and normalization of the

reaction heats with respect to the molar amount of injected ligand as well as for data fitting and binding parameter evaluation.

[0190] Finally, NMR spectroscopy was also carried out to analyse potential binding of BC007 to the control peptide, NRKRISN. The results thereof are shown in **Figure 9**. The NMR spectrum of BC 007 in combination with NRKRISN demonstrates the nearly complete absence of formation of the quadruplex structure of BC 007, recognizable in the missing imino signals between 11.5 and 12.5 ppm. For comparison: upper spectrum: BC 007 binding of the peptide sequence YRLF RK (sequence from the spike protein of SARS-CoV-2, theoretical pI value of 11.0).

[0191] Substances were dissolved in 0.5 ml pure H₂O/D₂O mixture without any additives. The NMR data investigating the interaction of BC 007 with this sequence-section of a SARS-CoV-2 protein was acquired at 600 MHz on a Bruker AV600 spectrometer (Bruker Biospin, Rheinstetten, Germany) in 90/10 H₂O/D₂O at 298K. The solvent signal was suppressed using the Watergate w5 pulse sequence included in the Bruker pulse program zgpgw5. Acquisition parameters included: time domain = 65K, number of scans = 512, sweep width = 24 ppm and 90° high power pulse = 13.8 µs.

5. Identification and characterization of GPCR autoantibodies in sera of patients having recovered from active SARS-CoV-2 infections

[0192] Sera were obtained from 25 patients after recovery from acute disease as confirmed by PCR. 23 patients were suffering from post-COVID-19 symptoms, while 2 patients were symptom-free.

[0193] As a safety-precaution, the COVID-19 patient sera were heat inactivated for 30 min at 56 °C before use. Afterwards, 0.4 mL of the samples were dialysed against 1 L of dialysing buffer (0.15 M NaCl, 10 mM phosphate buffer, pH 7.4; Membra-Cel MD 44, 14 kDa, Serva) for 24 hours to remove low-molecular weight bioactive compounds and peptides. Finally, 40 µL of the dialysed samples were added to the bioassay (final dilution of 1:50).

[0194] For the identification and characterisation of GPCR-fAABs, a bioassay was used, as described in great detail by Davideit et al. (Davideit H et al (2019) Determination of Agonistically Acting Autoantibodies to the Adrenergic Beta-1 Receptor by Cellular Bioassay. *Methods Mol Biol* 1901:95-102. https://doi.org/10.1007/978-1-4939-8949-2_8) and Wenzel et al. (Wenzel K, Schulze-Rothe S, Haberland A, et al (2017) Performance and in-house validation of a bioassay for the determination of beta1-autoantibodies found in patients with cardiomyopathy. *Heliyon* 3:e00362. <https://doi.org/10.1016/j.heliyon.2017.e00362>) for GPCR-fAABs against the beta1-adrenoceptor, and analogously for other GPCR-fAABs (see also Wallukat et al. (2018) *PLoS ONE* 13:e0192778) for the parallel determination of several GPCR-fAABs

[0195] After contact with the respective autoantibodies, a change in basal beating rate of spontaneously beating cardiomyocytes expressing GPCR was used as the measuring signal. The receptor specificity was checked by either subsequent addition of specific receptor blockers, resulting in an annulation of this effect, or by addition of corresponding receptor-epitope-competing extracellular loop peptides. In detail: for the specification of the β₂-fAABs, the receptor antagonist ICI118.551 (0.1µM) was used and also neutralizing peptides corresponding to the first or second extracellular loop of the human β₂-adrenoceptor.

[0196] The effect of the negative chronotropic muscarinic M2 receptor-autoantibody (M2-fAAB) was blocked by atropine (1 μ M). Losartan (1 μ M) blocked the effect of the positive chronotropic AT1-fAAB and A779 (1 μ M) blocked the effect of the negative chronotropic MAS-fAAB. For the identification of the MAS-fAAB, additional competing peptides corresponding to the first and second extracellular loop of the human MAS receptor were exploited.

[0197] ETA-fAABs were identified by blocking their negative chronotropic effects through the addition of the specific endothelin receptor antagonist BQ123 (0.1 μ M) and also competing peptides corresponding to the first or second extracellular loop of the receptor, respectively.

[0198] The nociceptin receptor antagonist J113397 (0.1 μ M) was used to block the effects of the positive chronotropic NOC-fAAB and also competing peptides corresponding to the first or second extracellular loop. Addition of 1 μ M urapidil or prazosin abolished the positive chronotropic effect of α 1-fAABs. For all peptides 2 μ L of a stock solution of 100 μ g/mL was added to 40 μ L of the corresponding GPCR-fAAB sample and incubated for 30min before the mixture was transferred to the cells.

[0199] Several different GPCR-fAABs were identified in the 25 sera of recovered COVID-19 patients. All 25 investigated patients had between 2 and 7 different GPCR-fAAB (Figure 10).

[0200] Two functionally active autoantibodies that were seen in almost all investigated patients, were directed against the β 2-adrenoceptor (β 2-fAAB) and the muscarinic M2 receptor (M2-fAAB). These fAABs induced a positive and a negative chronotropic response on their targeted receptors, respectively.

[0201] Two other fAABs that were also present in 23 (92%) of the 25 investigated post-COVID-19 patients were directed against the angiotensin II AT1 receptor (fAT1-AAB) and the angiotensin 1-7 MAS receptor (MAS-AAB). These receptors belong to the renin angiotensin system (RAS) and cause a positive and negative chronotropic effect, respectively, when targeted by the respective fAABs.

[0202] Post-infection hair loss (alopecia) was experienced by 8 of the recovered patients. In sera of these patients, three additional GPCR-fAABs were discovered: the negative chronotropic ETA-fAAB (4/8), the positive chronotropic NOC-fAAB (5/8), and the positive chronotropic α 1-AAB (3/8). Not every alopecia patient showed all three of these GPCR-fAABs. Instead, their occurrence varied, and a pattern is not yet detectable. As shown in Figure 10, 2 of the 25 investigated post COVID-19 patients developed fAABs without showing any symptoms.

[0203] A continuing fatigue-like symptom, persisting long after virus follow-up tests are negative, was a frequently reported impairment in patients of this study (17/25). For patients suffering from a classical coronavirus-independent fatigue syndrome, the occurrence of β 2-fAABs, M2-fAABs and, in some cases, also ETA-fAABs has already been reported before.

[0204] Here, almost all investigated sera contained β 2-fAABs and M2-fAABs. The combination of β 2-fAABs and M2-fAABs have also been identified in sera of patients suffering from PoTS and dysautonomia, both of which are conditions now observed in post-COVID-19 patients (3/25 and 2/25, respectively, not overlapping).

[0205] Furthermore, this combination of β 2-fAABs with M2-fAABs had also been identified before by the inventors, in patients with complex regional pain syndrome (CRPS), in patients suffering from narcolepsy type 1, here additionally with the NOC-fAAB in 9 of 10 cases and in patients with small fibre diseases.

[0206] Two of the identified GPCR-fAABs, observed in over 90% of the investigated COVID-19 patient sera (23/25), were directed against receptors of RAS, namely the angiotensin II AT1 receptor and the angiotensin (1-7) MAS receptor. These vasoactive AT1-fAABs had been identified before in patients with malignant hypertension, therapy-resistant hypertension, preeclampsia, and kidney diseases.

[0207] This data already indicates an important role of GPCR-AABs in the development of long COVID disease symptoms. Accordingly, BC007 as an established active agent against the detrimental effects of such antibodies appears to be a promising treatment option for patients suffering from long COVID symptoms.

6. Characterization of GPCR-AAB activity in Long-COVID-19 serum samples before and after administration of aptamer BC 007 (SEQ ID NO. 1)

Sample Preparation

[0208] Sera from patients having overcome COVID-19 but suffering from persisting symptoms associated with long COVID were heat-inactivated for 30 min at 56 °C before use as a safety measure. Afterwards, 0.4 mL of the samples were dialysed against 1 L of dialysing buffer (0.15 M NaCl, 10 mM phosphate buffer, pH 7.4; Membra-Cel MD 44, 14 kDa, Serva) for 24 hours to remove low-molecular weight bioactive compounds and peptides.

Bioassay of Spontaneously Beating Neonatal Rat Cardiomyocytes for the Measurement of GPCR-AAB activity in Long-COVID-19 serum samples (Cardiomyocyte Beat Rate Assay, CBRA-LC).

[0209] For estimation of GPCR-AAB in sera of Long-COVID-19 patients, 40 μ L of the dialysed samples were added to the bioassay (final dilution of 1 :50). The chronotropic effect of the AABs was measured following the principle of the CBRA as described in Wallukat G, and Wollenberger A (1987) Biomed Biochim Acta 46:S634-639.

[0210] For the determination of a combination of different GPCR-AABs in one sample, the measurement principles described in Wallukat G et al. (2018) PLoS ONE 13:e0192778., Wallukat G et al. (2019) Methods Mol Biol 1955:247-261, and Orjatsalo M et al. (2021) Sleep Med 77:82-87. had been applied.

[0211] For the assay, monolayers of neonatal rat cardiomyocytes are prepared and cultured in 12.5 cm² Falcon flasks. At first, the basal beating rate of six cardiomyocyte clusters was visually

determined and recorded. For the measurement of the GPCR-AABs expressing a positive chronotropic response, the cells are preincubated with a cocktail of receptor blockers, blocking all negative chronotropic GPCR-AAB effects (1 μ M Atropin blocking M2-AAB, 0.1 μ M BQ123 blocking ETA-AAB, and 1 μ M A779 blocking MAS-AAB).

[0212] After addition of 40 μ L of the dialysed samples (dilution 1:50) and incubation for 1 hr at 37°C, the positive chronotropic response was measured again at the same clusters. The difference to the basal rate was expressed as delta pulse rate [Δ PR / min]. Subsequent gradual addition of receptor blockers blocking the positive chronotropic effect of beta2-AAB (0.1 μ M ICI118,551), AT1-AAB (1 μ M Losartan), alpha1-AAB (1 μ M urapidil or prazosin) and nociceptin-AAB (0.1 μ M J113397) has determined the proportion of the respective AAB in the total activity of the positive chronotropic GPCR-AABs.

[0213] For the determination of the GPCR-AAB showing a negative chronotropic response, the test was conducted *vice versa*. The cells were initially pretreated using a cocktail of receptor blockers, blocking the positive chronotropic response (0.1 μ M ICI118,551 blocking beta2-AAB, 1 μ M Losartan blocking AT1-AAB, 1 μ M urapidil or prazosin blocking alpha1-AAB, and 0.1 μ M J113397 blocking nociceptin-AAB), before 40 μ L (1:50) of the prepared patient serum was added.

[0214] In case of resulting negative chronotropic response, a subsequent gradual addition of Atropin (M2-AAB), BQ123 (ETA-AAB), and A779 (MAS-AAB) has determined the proportion of the respective AAB in the total activity of the negative chronotropic GPCR-AABs.

Follow-up of Long-COVID patients after treatment with BC007

[0215] In order to determine treatment success or treatment effects, patients were followed up at given time intervals (6h, 2d, 7d, 30d) following administration of BC007. Again, patient samples were added to cardiomyocytes pre-treated with receptor-blocker cocktails for either all positive chronotropic GPCR-AABs or all negative chronotropic GPCR-AABs.

[0216] If no opposite chronotropic sample effect could be detected as being caused by patient sera (positive chronotropic response on cardiomyocytes blocked for all negative chronotropic GPCR-AABs, or *vice versa*), then this could be interpreted as indicating an absence of corresponding GPCR-AABs in this sample.

[0217] However, in such cases, a discrimination of single GPCR-AABs with respective single receptor blockers is no longer possible.

	Before BC007 administration	After 6 hours	After two days	After seven days	After thirty days
Total positive	8.17 U	2.09 U	0.67 U	0.6 U	0.17 U
β 2-AAB	4.34 U	0.89 U	---	---	---
AT1-AAB	1.66 U	---	---	---	---
α 1-AAB	2.17 U	1.20 U	---	---	---
Total	- 5.50 U	- 1.83 U	0.67 U	0.6 U	0.17 U

	Before BC007 administration	After 6 hours	After two days	After seven days	After thirty days
negative					
M2-AAB	- 1.83 U	---	---	---	---
MAS-AAB	- 3.67 U	- 1.83 U	---	---	---

[0218] For the values indicated in the Table above and based on the experimental conditions, any value above 1.17 is considered as presence of the tested autoantibody or autoantibodies, and any value below this threshold value is considered as absence thereof.

[0219] This experiment demonstrates that GPCR autoantibodies which were found and identified in patients having overcome COVID-19 and suffering from symptoms persisting after infection and being associated with long COVID in fact have direct and measurable effects on G-protein coupled receptors as shown by the rat cardiomyocyte assay.

[0220] Further, it could clearly be demonstrated that administration of BC007 to long COVID patients is able to counteract the effects of said GPCR autoantibodies, presumably by specific binding and persistent neutralization of such autoantibodies.

[0221] This data represents experimental evidence for the foundation of the present invention that BC007 (SEQ ID NO. 1) is able to neutralize GPCR autoantibodies appearing as one of the main causative agents of long COVID after an infection with SARS-CoV-2 has been overcome. Similar observations have been made and published by the present inventors in Hohberger et al. (2021) Front. Med. 8:754667.

[0222] Taken together, BC007 and its specific and efficient action against GPCR autoantibodies represents one of the most promising treatment options for patients suffering from persisting disease symptoms of the long COVID syndrome after having overcome an infection with SARS-CoV-2.

[0223] Even more intriguingly, the function of BC007 against the infection with SARS-CoV-2 and the progression thereof together with its function against long COVID symptoms make it even more suitable for the treatment of ongoing infections as well as symptoms potentially persisting after the infection has been overcome.

REFERENCES CITED IN THE DESCRIPTION

Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

- **LU, G. et al.** Nature, 2013, vol. 500, 227-231 [0006]
- **ZHOU, P. et al.** Nature, 2020, vol. 579, 270-273 [0007]
- **WALLS, A. C. et al.** Cell, 2020, [0008]
- **HOFFMANN, M. et al.** Cell, [0008]
- **CLAUSEN et al.** Cell, 2020, vol. 183, 1043-1057 [0010]
- **GONZÁLEZ, V.M. et al.** Use of Aptamers as Diagnostics Tools and Antiviral Agents for Human Viruses Pharmaceuticals, 2016, 9- [0013]
- **ZOU et al.** Application of Aptamers in Virus Detection and Antiviral Therapy Front Microbiol, vol. 10, 1462- [0013]
- **NEGRI et al.** Direct Optical Detection of Viral Nucleoprotein Binding to an Anti-Influenza Aptamer Anal Chem., 2012, vol. 84, 135501-5508 [0014]
- **ACKERMANN M. et al.** N Engl J Med., 2020, [0015]
- **VARGA Z et al.** The Lancet, 2020, [0015]
- **WICHMANN D et al.** Annals of Internal Medicine, 2020, [0015]
- **CARFI ABERNABEI RLANDI F** Gemelli Against COVID-19 Post-Acute Care Study Group (2020) Persistent Symptoms in Patients After Acute COVID-19 JAMA, vol. 324, 603-605 [0016]
- **PUNTMANN VOCARERJ MLWIETERS I et al.** Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) JAMA Cardiol, 2020, [0016]
- **KHAMSI R** Nature, 2021, vol. 590, 784429-31 [0019]
- **ROXO, C. et al.** G-Quadruplex-Forming Aptamers-Characteristics, Applications, and Perspectives Molecules, 2019, 24- [0067]
- **PADMANABHANTULINSKY** Acta Crystallogr D Biol Crystallogr, 1996, vol. 52, 272-282 [0073]
- **KARLINALTSCHUL** Proc. Natl. Acad. Sci. USA, 1993, vol. 90, 5873-5877 [0077]
- **ALTSCHUL et al.** J. Mol. Biol., 1990, vol. 215, 403-410 [0077]
- **ALTSCHUL et al.** Nucleic Acids Res., 1997, vol. 25, 3389-3402 [0077]
- **KEEFE AD et al.** Nat Rev Drug Discov., 2010, vol. 9, 7537-50 [0091]
- **MAYER G** Angew Chem Int Ed Engl., 2009, vol. 48, 152672-89 [0091]
- **MAYER, G.FAMULOK M.** Pharmazie in unserer Zeit, 2007, vol. 36, 432-436 [0091]
- **UHLMANN, E. et al.** Chem. Rev., 1990, vol. 90, 543- [0093]
- **Protocols for Oligonucleotides and Analogs Synthesis and Properties & Synthesis and Analytical Techniques** Humana Press 1993 0000 [0093]
- **HUNZIKER, J. et al.** Mod. Syn. Methods, 1995, vol. 7, 331-417 [0093]
- **CROOKE, S. et al.** Ann. Rev. Pharm. Tox., 1996, vol. 36, 107-129 [0093]
- **XU X et al.** Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design Nucleic Acids Res, 2003, vol. 31, 7117-7130 7118- [0135]
- **WANG YANIRUDHAN VDU RCUI QRONG L** RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target J Med Virol, 2020, [0137]
- **WU CLIU YYANG YZHANG PZHONG WWANG YWANG QXU YLI MLI X** Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods Acta Pharm Sin, 2020, 8- [0137]
- **ULRICH H** DNA and RNA aptamers as modulators of protein function Medicinal Chemistry (Sharjah (United Arab Emirates)), 2005, vol. 1, 199-208 [0140]

- **STERLING TIRWIN JJ**Journal of Chemical Information and Modeling, 2015, vol. 55, 112324-2337 [\[0144\]](#)
- **KOWALEWSKI JRAY AH**Helvion, 2020, vol. 6, e04639- [\[0145\]](#)
- **WU CLIU YYANG YZHANG PZHONG WWANG YWANG QXU YLI MLI X**Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methodsActa Pharm Sin B, 2020, [\[0147\]](#)
- **POKHREL RCHAPAGAIN PSILTBERG-LIBERLES J**Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2J Med Microbiol, 2020, [\[0147\]](#)
- **AFTAB SOGHOURI MZMASOOD MUHAIDER ZKHAN ZAHMAD AMUNAWAR N**Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approachJournal of Translational Medicine, 2020, vol. 18, 275- [\[0147\]](#)
- Biacore Assay Handbook [\[0153\]](#)
- **ALI MHELSHERBINY MEEMARA M**Updates on Aptamer ResearchInternational Journal of Molecular Sciences, 2019, 20- [\[0155\]](#)
- **STOLTENBURG RNIKOLAUS NSTREHLITZ B**Capture-SELEX: Selection of DNA Aptamers for Aminoglycoside AntibioticsJournal of Analytical Methods in Chemistry, 2012, vol. 2012, 415697- [\[0155\]](#)
- **ZHANG YLAI BSJUHAS M**Recent Advances in Aptamer Discovery and ApplicationsMolecules, 2019, 24- [\[0156\]](#)
- **SCHULTZE, P. et al.**Three-dimensional solution structure of the thrombin-binding DNA aptamer d(GGTTGGTGTGGTTGG)J. Mol. Biol., 1994, vol. 235, 1532-1547 [\[0163\]](#)
- **WEISSHOFF, H. et al.**Characterization of Aptamer BC 007 Substance and Product Using Circular Dichroism and Nuclear Magnetic Resonance SpectroscopyJ Pharm Sci., 2018, [\[0163\]](#)
- **HERZOG et al.**Virology Journal, 2008, vol. 5, 138- [\[0167\]](#)
- **WANG et al.**Cell Research, 2020, vol. 30, 269-271 [\[0169\]](#)
- **BECKER et al.**Clin Drug Investig, 2020, vol. 40, 5433-447 [\[0173\]](#)
- All Eyes on Gilead**LANGRETH, ROBERT**Bloomberg BusinessweekBloomberg, L.P.20200514 [\[0174\]](#)
- **DAVIDEIT H et al.**Determination of Agonistically Acting Autoantibodies to the Adrenergic Beta-1 Receptor by Cellular BioassayMethods Mol Biol, 2019, vol. 1901, 95-102 [\[0194\]](#)
- **WENZEL KSCHULZE-ROTHER SHABERLAND A et al.**Performance and in-house validation of a bioassay for the determination of beta1-autoantibodies found in patients with cardiomyopathyHelvion, 2017, vol. 3, e00362- [\[0194\]](#)
- **WALLUKAT et al.**PLoS ONE, 2018, vol. 13, e0192778- [\[0194\]](#)
- **WALLUKAT GWOLLENBERGER A**Biomed Biochim Acta, 1987, vol. 46, S634-639 [\[0209\]](#)
- **WALLUKAT G et al.**PLoS ONE, 2018, vol. 13, e0192778- [\[0210\]](#)
- **WALLUKAT G et al.**Methods Mol Biol, 2019, vol. 1955, 247-261 [\[0210\]](#)
- **ORJATSAALO M et al.**Sleep Med, 2021, vol. 77, 82-87 [\[0210\]](#)
- **HOHBERGER et al.**Front. Med., 2021, vol. 8, 754667- [\[0221\]](#)

Patentkrav

- 5 **1.** Aptamer til anvendelse i terapi af et individ ved at behandle, helbrede eller forebygge sygdomssymptomer forbundet med langvarig COVID hos en patient, der har overvundet en infektion med en virus fra *Coronaviridae*-familien, hvor aptameren omfatter en nukleinsyresekvens af SEQ ID No. 1 (GGT TGG TGT GGT TGG) og/eller en nukleinsyresekvens, der er mindst 80% identisk med SEQ ID No. 1.
- 10 **2.** Aptamer til anvendelse ifølge krav 1, hvor sygdomssymptomerne omfatter en eller flere fra gruppen omfattende neurologiske symptomer, såsom kronisk træthedssyndrom, posturalt ortostatisk takykardisyndrom (PoTS), dysautonomi, tremor, opmærksomhedsunderskud, anomisk afasi, neuropati, tværgående myelitis, akut nekrotiserende myelitis og Guillain-Barré-syndrom, kardio-
- 15 vaskulære symptomer, såsom myokardiebetændelse, arytmi, takykardi, bradykardi, hypertension og atrioventrikulær (AV) blokering, dermatologiske symptomer, såsom alopeci og eksem, eller gastrointestinale sygdomme.
- 20 **3.** Aptamer til anvendelse ifølge et hvilket som helst af kravene 1 eller 2, hvor aptameren anvendes til at inhibere interaktionen af autoantistoffer, der er specifikke for en G-proteinkoblet receptor med dens målproteiner.
- 25 **4.** Aptamer til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor aptameren er til anvendelse i behandlingen af en patient, hvor autoantistoffer mod G-proteinkoblede receptorer kan påvises.
- 30 **5.** Aptamer til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor patienten udviser funktionelle autoantistoffer mod G-proteinkoblede receptorer, fortrinsvis funktionelle autoantistoffer, der er specifikke for en hvilken som helst af de humane G-proteinkoblede receptorer af adrenerg alfa-1-receptor, adrenerg beta-2-receptor, endothelin-1-ETA-receptor, muskarin M2-receptor,

angiotensin-II-AT1-receptor, MAS-receptor og/eller nociceptionsreceptoren, mere fortrinsvis for en hvilken som helst af den adrenerge beta-2-receptor, muskarin M2-receptor, angiotensin-II-AT1-receptor, MAS-receptor, især fortrinsvis hvor patienten udviser et antistofmønster, der omfatter funktionelle autoantistoffer, der er specifikke for hver af den adrenerge beta-2-receptor, muskarin M2-receptor, angiotensin-II-AT1-receptor og MAS-receptor.

6. Aptamer til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor patienten har overvundet en infektion med SARS-CoV-2.

7. Aptamer til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor aptameren omfatter en nukleinsyresekvens af SEQ ID No. 1 (GGT TGG TGT GGT TGG).

8. Aptamer til anvendelse ifølge krav 7, hvor aptameren består af en nukleinsyresekvens med SEQ ID No. 1 (GGT TGG TGT GGT TGG).

9. Aptamer til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor patienten har overvundet en infektion med SARS-CoV-2, og hvor aptameren omfatter en nukleinsyresekvens af SEQ ID No. 1 (GGT TGG TGT GGT TGG).

10. Aptamer til anvendelse ifølge krav 9, hvor aptameren består af en nukleinsyresekvens med SEQ ID NO. 1 (GGT TGG TGT GGT TGG).

11. Aptamer til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor aptameren har antikoagulerende aktivitet, fortrinsvis hvor aptameren forhindrer eller reducerer mikrothromboser.

12. Aptamer til anvendelse ifølge et hvilket som helst af kravene 1 til 11, hvor aptameren har antikoagulerende aktivitet, fortrinsvis hvor aptameren er i stand

til at forlænge koagulationstiden målt som partiel tromboplastintid (PTT) af humant kalibreringsplasma til 60 sekunder eller mere ved en aptamerkoncentration på 0,03 mg/ml, og/eller hvor aptameren er i stand til at sænke protrombintiden (hurtig værdi) af humant kalibreringsplasma til 40% eller mindre ved en aptamerkoncentration på 0,03 mg/ml

13. Farmaceutisk sammensætning omfattende en aptamer som defineret i et hvilket som helst af kravene 1 til 12 og mindst én farmaceutisk acceptabel excipiens til anvendelse i terapi af et individ ved behandling, helbredelse eller forebyggelse af sygdomssymptomer forbundet med langvarig COVID hos en patient, der har overvundet en infektion med en virus fra *Coronaviridae*-familien.

14. Farmaceutisk sammensætning til anvendelse ifølge krav 13, hvor patienten har overvundet en infektion med SARS-CoV-2.

DRAWINGS

Drawing




Figure 1




Figure 2






Figure 3

**Figure 4**

A



B




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9

Patient no.	Gen der	Age year	Room no.	Symptom class		Symptoms	Neuro- active AABs		Vascular AABs			Neuro- and vasoclitic AABs		RAS-specific AABs	
				Neuro ⁺	Cardio ⁺	Neuro ⁺	Nec- AAB	Re- AAB	Stk- AAB	Stk- AAB	Re-AAB ⁺	ATI- AAB	MAA- AAB ⁺		
1	f	48	1	X	X	Fatigue, Alopexia, Anomic aphasia	X	X	X	X	X	X	X	X	X
7	f	55	2	X	X	Fatigue, Alopexia	X	X	X	X	X	X	X	X	X
11	f	39	3	X	X	Fatigue, Alopexia	X	X	X	X	X	X	X	X	X
19	f	34	4	X	X	Fatigue, PoTS, Tremor	X	X	X	X	X	X	X	X	X
22	f	34	5	X	X	Fatigue, Alopexia	X	X	X	X	X	X	X	X	X
3	f	56	6	X	X	Fatigue, Attention deficit	X	X	X	X	X	X	X	X	X
21	f	28	7	X	X	Attention deficit, Tremor, Dysautonomia	X	X	X	X	X	X	X	X	X
18	f	53	8	X	X	Tremor, Attention deficit	X	X	X	X	X	X	X	X	X
20	m	54	9	X	X	Attention deficit	X	X	X	X	X	X	X	X	X
14	f	57	10	X	X	Fatigue, Anomic aphasia	X	X	X	X	X	X	X	X	X
23	f	59	11	X	X	Eczema, Alopexia	X	X	X	X	X	X	X	X	X
24	f	33	12	X	X	Fatigue, PoTS	X	X	X	X	X	X	X	X	X
2	m	42	13	X	X	Fatigue, Alopexia	X	X	X	X	X	X	X	X	X
4	m	50	14	X	X	Fatigue	X	X	X	X	X	X	X	X	X
5	f	45	15	X	X	Fatigue	X	X	X	X	X	X	X	X	X
6	f	36	16	X	X	Tremor, Alopexia, Dysautonomia	X	X	X	X	X	X	X	X	X
9	f	50	17	X	X	Fatigue	X	X	X	X	X	X	X	X	X
10	f	48	18	X	X	Fatigue	X	X	X	X	X	X	X	X	X
12	f	53	19	X	X	Fatigue, Attention deficit	X	X	X	X	X	X	X	X	X
15	f	46	20	X	X	Fatigue, Alopexia, Psychoneurology	X	X	X	X	X	X	X	X	X
17	f	49	21	X	X	Fatigue, PoTS, Tremor	X	X	X	X	X	X	X	X	X
25	f	58	22	X	X	Attention deficit, Neuropathy	X	X	X	X	X	X	X	X	X
13	f	26	23	X	X	Fatigue	X	X	X	X	X	X	X	X	X
8	m	71	24	X	X	Symptom free	X	X	X	X	X	X	X	X	X
16	m	54	25	X	X	Symptom free	X	X	X	X	X	X	X	X	X

Figure 10



A**B**

Figure 11

SEKVENSLISTE

Sekvenslisten er udeladt af skriftet og kan hentes fra det Europæiske Patent Register.

The Sequence Listing was omitted from the document and can be downloaded from the European Patent Register.

